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Introduction
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Research on cancer is an industry fueled by public funding (estimated 11 billion US dollar, 
2004/20051), private investment (estimated 3 billion US dollar by the top 24 pharmaceutical 
companies, 2004/20051), and the scientific vigor of the global research community.
Another essential resource for cancer research is clinical data from healthcare providers: 
data describing oncology patients, their treatments, and therapy results. This data highlights 
the successes of cancer research and where treatment improvements are necessary. It is a 
measurement directly at the focal point: the treatment of a cancer patient—for which the 
cancer research industry has been built and where all research projects coalesce. If enough 
clinical data is available, statistical data analysis can not only evaluate the quality of cancer 
treatments but also transform clinical data into information to drive future treatment 
decisions: based on data from previous patients, which treatment should a new patient receive 
to maximize their chance of survival? Which treatment will minimize the chance of negative 
side effects? Clinical data thus becomes an input for cancer research.
When the clinical data and treatment decision become complex, statistical analysts use 
abstract computational models to solve the research problem. At this point, the analyst 
delegates a part of their work to a machine which analyzes (learns) from this clinical data to 
find the correct answer. Such computational models form the basis for machine learning, an 
emerging subfield of statistics.
Machine learning
Machine learning is a statistical process in which computational algorithms identify patterns 
in datasets. Datasets, in our context of clinical data analysis, consist of characteristics 
describing the disease and treatment of multiple patients. The patterns identified by the 
algorithm allow further describing a patient, e.g., categorize patients into subgroups 
(clustering, an unsupervised machine learning technique) or predict the probability of survival 
after treatment (prediction modelling, a supervised machine learning technique). The machine 
learning algorithms treated in this thesis are supervised learning algorithms for prediction 
modelling (with exception of the nearest neighbor algorithms used in chapter 5). Many 
machine learning algorithms have been developed in the last decades and it is not always clear 
which algorithm is the most suitable for a given task. The second part of this thesis concerns 
the comparison of existing algorithms for prediction modelling in radiation oncology and the 
development of novel algorithms.
Machine learning is used successfully for many tasks outside medical research, e.g., automated 
language translation or image recognition, and has become increasingly popular in cancer 
research. Cancer research publications involving machine learning quintupled from 2010 to 
20171.
1 The relative number of publications listed on PubMed involving cancer or oncology and 
machine learning versus publications involving only cancer or oncology. Pubmed search 
(20.09.2018): ((cancer) OR oncology) AND (machine learning) versus ((cancer) OR 
oncology).
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Access to data and distributed learning
For a machine to learn and provide accurate answers to a cancer research question, e.g., which 
treatment provides the highest survival probability for a given patient, it needs to have access 
to large amounts of clinical data. Access to clinical data is difficult for multiple reasons2, for 
example:
• regulations protecting patient privacy: medical details should not become public;
• technical barriers: how to transfer large clinical data volumes?;
• lacking data standardization: information is stored in incompatible formats;
• competing interests: institutes do not share clinical data as it is a valuable resource for 
research;
• PR risks: sharing therapy results allows comparing performance across healthcare 
providers.
To overcome the regulatory and technical barriers, the concept of distributed machine 
learning can be employed. Instead of collecting all clinical data in a central database, 
which risks patient privacy violations, and then applying the machine learning algorithm, 
distributed learning uses a different approach: the data remains with the healthcare provider 
and the algorithm is sent to the data as proposed by Gaye et al. (2014)3. Figure 1 illustrates the 
distributed learning concept.
Learning
Coordinator
Learning
Connector
Data 
Warehouse
PACS
EMR
Other
Hospital C Hospital A
Hospital D
Hospital B
Learning
Connector
Learning
Connector
Learning
Connector
Figure 1. An example distributed learning infrastructure with four participating hospitals. All hospitals installed a 
Learning Connector that communicates with the Learning Coordinator server outside the hospitals. The Learning 
Connector receives machine learning algorithms and applies them on the hospital’s data (extracted from various 
local databases), the learning results are sent back to the Learning Coordinator. Adapted from Lambin et al. (2017)4.
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In this way, patient-specific information does not leave the healthcare provider because the 
machine only learns and stores abstract concepts which are equivalent to aggregated patient 
information. Furthermore, no large data volumes need to be exchanged except for the 
moderately sized machine learning algorithm. However, developing a distributed learning 
infrastructure is a technical challenge in itself. Furthermore, already established machine 
learning algorithms need to be redesigned to function in a distributed learning setting. We 
therefore distinguish between two types of learning algorithms
• centralized learning algorithms: learning on data in a single database;
• distributed learning algorithms: learning on data spread over multiple databases.
The implementation of a distributed learning infrastructure and algorithms forms the first 
part of this thesis. Centralized learning algorithms are studied in the second part of this thesis.
Radiation oncology
Access to clinical data is an issue for medical research in general and distributed learning 
potentially offers solutions for all medical specializations. This thesis focusses on oncology and 
radiation oncology (or radiotherapy) in particular. Radiotherapy, surgery, and chemotherapy 
are the most frequently used cancer treatments. In radiotherapy, the tumor is irradiated either 
by an external radiation beam or by a radiation source that is surgically inserted in close 
proximity of the tumor (brachytherapy). The radiation causes DNA damage in the tumor and 
surrounding tissues. The radiation treatment is often repeated multiple times. DNA damage 
in the surrounding tissues can cause negative side effects, for example, swallowing problems 
(dysphagia) due to irradiation of the esophagus during external beam lung radiotherapy. The 
prediction of side effects and patient survival (i.e. treatment outcomes) are the main goal of 
machine learning algorithms discussed in this thesis.
This thesis
This thesis has two main subjects:
• the development and implementation of a distributed learning infrastructure across 
international radiotherapy institutes (Chapters 2-3);
• studies of centralized machine learning algorithms (Chapters 4-5).
The latter comprises empirical analyses of existing classification algorithms for treatment 
outcome prediction and the development of novel machine learning algorithms. See Table 1 
for an overview.
• Chapter 2 outlines the distributed learning concept and initial results. We present the 
implementation of a distributed support vector machine algorithm described by Boyd 
et al. (2010)5 and its application in our first distributed learning project in four institutes 
spanning three countries (Belgium/Germany/The Netherlands). This chapter forms one 
of our multiple early studies6,7 on the distributed learning infrastructure.
• Chapter 3 presents results from a large-scale follow-up study across eight institutes in 
five countries (England/Italy/The Netherlands/The People’s Republic of China/Wales). It 
introduces a new implementation of a distributed logistic regression algorithm (Boyd et 
al. (2010)5) applied on survival and cancer staging data of more than 20 000 non-small 
cell lung cancer patients.
• Chapter 4 presents results of an empirical comparison of binary classification algorithms 
for modelling treatment outcomes in radiotherapy on 12 datasets.
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• Chapter 5 introduces novel kernelized classification and regression algorithms which 
allow exploiting (bioinformatic) simulation models in machine learning algorithms. We 
study these algorithms in four exemplary cases from bioinformatics and network flow 
optimization.
• Chapter 6 discusses challenges for the acceptance and sustainability of distributed 
learning infrastructures followed by an appraisal of machine learning in radiotherapy 
research.
Table 1. Thesis structure.
Introduction Original research Discussion
Chapter 1 Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6
Distributed learning Centralized learning
Infrastructure development
Algorithm implementation Algorithm comparison Algorithm development
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Distributed learning
Infrastructure and distributed learning 
methodology for privacy-preserving 
multi-centric rapid learning health care: 
euroCAT
Chapter 2
Adapted from Deist, Timo M., et al. “Infrastructure and distributed learning 
methodology for privacy-preserving multi-centric rapid learning health care: 
euroCAT.” Clinical and translational radiation oncology 4 (2017): 24-31.
Timo M. Deist, A. Jochems, Johan van Soest, Georgi Nalbantov, Cary Oberije, Seán 
Walsh, Michael Eble, Paul Bulens, Philippe Coucke, Wim Dries, Andre Dekker, 
Philippe Lambin
Abstract
Machine learning applications for personalized medicine are highly dependent on access to 
sufficient data. For personalized radiation oncology, datasets representing the variation in the 
entire cancer patient population need to be acquired and used to learn prediction models. 
Ethical and legal boundaries to ensure data privacy hamper collaboration between research 
institutes. We hypothesize that data sharing is possible without identifiable patient data 
leaving the radiation clinics and that building machine learning applications on distributed 
datasets is feasible. We developed and implemented an IT infrastructure in five radiation 
clinics across three countries (Belgium, Germany, and The Netherlands). We present here a 
proof-of-principle for future ‘big data’ infrastructures and distributed learning studies. Lung 
cancer patient data was collected in all five locations and stored in local databases. Exemplary 
support vector machine (SVM) models were learned using the Alternating Direction 
Method of Multipliers (ADMM) from the distributed databases to predict postradiotherapy 
dyspnea grade ≥ 2. The discriminative performance was assessed by the area under the curve 
(AUC) in a five-fold cross-validation (learning on four sites and validating on the fifth). The 
performance of the distributed learning algorithm was compared to centralized learning 
where datasets of all institutes are jointly analyzed. The euroCAT infrastructure has been 
successfully implemented in five radiation clinics across three countries. SVM models can 
be learned on data distributed over all five clinics. Furthermore, the infrastructure provides a 
general framework to execute learning algorithms on distributed data. The ongoing expansion 
of the euroCAT network will facilitate machine learning in radiation oncology. The resulting 
access to larger datasets with sufficient variation will pave the way for generalizable prediction 
models and personalized medicine.
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Introduction
Medical research revolves around accumulation and analysis of (patient) data. Collecting 
sufficient quantities of data to explain a phenomenon is arguably a major impediment to 
scientific progress in a technology-driven discipline such as radiation oncology. This obstacle 
becomes even more eminent in light of the recent adoption of machine learning1 to foster the 
goal of personalized medicine: machine learning algorithms require access to large databases 
with sufficient variation in the collected data to answer complex research questions. Single 
institutes struggle to collect the necessary data volumes with sufficient diversity to learn from. 
Furthermore, data collected in radiation oncology is influenced and biased by technological 
(e.g., vendor-specific properties2), human (e.g., local patient characteristics, physician’s 
opinions3), as well as organizational (e.g., treatment guidelines) factors which can change 
rapidly.
Research questions in such contexts may remain unanswerable by isolated data collection 
efforts: the data may be too biased or simply lack the necessary variation to successfully 
model relationships between the collected variables. Data homogeneity may not only be 
an issue for single institutes but nationwide due to national treatment guidelines4. Hence, 
generalizable machine learning models to answer these research questions should be created 
by incorporating data from multiple institutes in a continuous manner (i.e. rapid learning 
health care5). Systematic data sharing among research institutes will become an indispensable 
means for personalized medicine to thrive in radiation oncology. At present, data sharing is 
characterized by one-off exchanges of datasets with limited standardization of data collection 
and data characterization. Further, data sharing is impeded by each institute’s legal and ethical 
concern to protect their patients’ privacy rights. In this study, we present euroCAT, an IT 
infrastructure for systematic data sharing among research institutes. A video summary is 
available here: https://youtu.be/ZDJFOxpwqEA. The hypotheses of the study are
1. Data sharing for machine learning is possible without identifiable patient data leaving an 
institute’s IT systems. Thus, the institutes remain in control of their data, preserve data 
privacy, and thereby overcome legal and ethical issues common to other forms of data 
exchanges.
2. Running machine learning applications on these data is feasible and, given the appropriate 
methodology, the resulting models only minimally differ from centrally learned models, 
which makes efforts to centralize data largely unnecessary. As an example, support vector 
machines (SVM) predicting severe dyspnea after radiotherapy (henceforth simply called 
dyspnea) are learned from the data provided in five institutes.
The aim of the study was to deploy the euroCAT system in five partner institutions within 
three European countries (Belgium, Germany, and The Netherlands) and in four languages 
(Dutch, English, French, and German) and test the above hypotheses. euroCAT focusses on 
multi-centric machine learning in radiation oncology, similar work to implement privacy-
preserving data analysis exists, e.g., for Genome-Wide Association Studies (GWAS)6. 
Constable et al. (2015) concisely discuss existing literature for distributed learning and the 
accompanying risks. A web service for distributed logistic regression analysis is presented by 
Jiang et al. (2013)7 to facilitate collaborative regression analysis.
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Material & methods
euroCAT infrastructure
Institutes within the euroCAT network (a site) dedicate a server within their IT infrastructure 
that hosts the local databases and local learning connector (Varian Medical Systems, Palo Alto, 
USA). The global learning environment (Varian Learning Portal) spans the sites, and connects 
a central server (the master) outside the sites’ IT infrastructure to the learning connectors 
inside the sites. Master and sites communicate via file-based, asynchronous messaging. The 
user interacts with the learning environment via a web browser-based interface in which s/he 
can upload learning applications (MATLAB, MathWorks, Natick, MA, USA) and can initiate 
machine learning runs. Every learning application consists of two parts, one site algorithm 
which runs inside the sites’ infrastructure and interacts with the learning connector and one 
master algorithm which runs in the global learning environment and can send and receive 
messages to and from the site algorithms.
Data
Each participating center (Aachen (Germany), Eindhoven (The Netherlands), Hasselt 
(Belgium), Liège (Belgium), and Maastricht (The Netherlands)) was asked to retrospectively 
select at least 50 patients which fulfilled the inclusion criteria (non-small cell lung cancer, 
high-dose radiotherapy, no surgical treatment). The centers were provided with an overview 
of variables that were needed for the study. Initially, survival outcome, dysphagia outcome, and 
dyspnea outcome were scored. For this proof-of-principle paper, we only used the dyspnea 
outcome. The data was stored in a spreadsheet. An euroCAT researcher visited each center 
and manually checked 20% of the collected data for inconsistencies/mistakes. Post-treatment 
dyspnea was recorded for 268 patients. Given availability in the databases, three features were 
manually selected to construct an exemplary prediction model for post-treatment severe 
dyspnea: lung function tests (FEV1 (in %), forced expiratory volume in 1 s, in %, adjusted for 
age and gender), cardiac comorbidity (non-hypertension cardiac disorder at baseline, for which 
treatment at a cardiology department has been given), and timing of chemotherapy. Severe 
dyspnea was defined as ≥ Grade 2 dyspnea after treatment. The variables are listed in Table 1.
From the spreadsheets, data was extracted using an open source data warehousing tool 
(Pentaho) and stored in an open-source database (PostgreSQL). From this database, data 
elements were mapped to the Semantic Web data model (Resource Description Framework, 
RDF) using an open source tool (D2RQ) and stored in an open-source RDF store (Sesame, 
Eclipse RDF4J). During mapping to RDF the data elements were coded using Uniform 
Resource Identifiers (URIs) which are defined in a domain ontology (Radiation Oncology 
Ontology) and reference ontologies (NCI Thesaurus, Unit Ontology) in the Web Ontology 
Language (OWL, available on the Bioportal8). The learning connector uses the Semantic Web 
query language SPARQL to query data from the RDF store9 and can parse that data to the site 
learning algorithm.
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Table 1. Overview of patient characteristics per hospital.
Maastricht Eindhoven Hasselt Liège Aachen
Variable Count % Count % Count % Count % Count %
Post-RT Dyspnea                    
< 2 89 72% 50 89% 8 57% 20 61% 36 86%
≥ 2 34 28% 6 11% 6 43% 13 39% 6 14%
Missing 0 0% 0 0% 0 0% 0 0% 0 0%
Cardiac Comorbidity
No 90 73% 44 79% 2 14% 27 82% 24 57%
Yes 33 27% 12 21% 3 21% 6 18% 12 29%
Missing 0 0% 0 0% 9 64% 0 0% 6 14%
Chemotherapy Timing
None 16 13% 5 9% 3 21% 0 0% 2 5%
Sequential 22 18% 24 43% 2 14% 2 6% 4 10%
Concurrent 85 69% 27 48% 8 57% 31 94% 33 79%
Missing 0 0% 0 0% 1 7% 0 0% 3 7%
FEV1 (in %)                    
Mean & Standard Dev 78 21 80 25 80 25 72 23 66 19
Missing Count & 
Percentage 0 0% 20 36% 2 14% 0 0% 20 48%
Figure 1. Distributed learning flow in euroCAT.
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Distributed learning
The process of carrying out distributed learning inside euroCAT is presented schematically 
in Fig. 1. At each iteration, the data stored at different sites is processed simultaneously 
and separately. Updated model parameters are then sent from each site to the master. At 
the master, an algorithm compares the model parameters and updates them further. The 
algorithm also checks whether the learning process has converged sufficiently (according to 
pre-set convergence criteria). If the convergence criteria are not yet met, the master sends 
the parameters back to each of the sites. Once the sites receive updated parameters, they are 
used as a starting point for adjusting the model parameters further (given the local data) 
once again. This completes one iteration cycle. The learning iterations continue until the 
convergence criteria are satisfied. Using this infrastructure allows models to use data for 
learning without transferring these data across the network. The learned model is a support 
vector machine (SVM) classifier, solved with the Alternating Direction Method of Multipliers 
(ADMM) method10.
Support vector machines (SVM)  
& the Alternating Direction Method of Multipliers (ADMM)
A support vector machine determines two parallel hyperplanes, forming a ‘border’ which 
separates the feature space into two large regions and a margin between the planes. Each 
dimension of this feature space represents one patient feature (e.g., FEV1 (in %) or cardiac 
comorbidity) and each patient is represented by one point in this space. For simple problems, 
the intention would be to identify hyperplanes that separate all patients with dyspnea from the 
group of patients without dyspnea. This is not possible in most cases, therefore the objective 
becomes to find hyperplanes such that
• most of the dyspneic patients are on one and non-dyspneic patients are on the other side;
• if there is a patient on the ‘wrong’ side of the border, the distance to the border is as small 
as possible;
• the border between the groups of dyspneic and non-dyspneic patients is as large as 
possible.
The optimal hyperplanes (dw+b=1 and dw+b=-1, where d are the features of a patient) are 
determined by a vector of coefficients (w,b) that minimizes a cost function under a set of 
constraints (see Appendix A for details). Boyd et al. (2011)10 discuss a distributed formulation 
of a support vector machine using the Alternating Direction Method of Multipliers (ADMM) 
and provide MATLAB code11. The ADMM algorithm gained popularity in the machine 
learning community as it allows to split up large datasets into smaller portions and distribute 
the analysis over multiple machines. In our multi-centric learning context, the same property 
is exploited to overcome the restriction that data may not be centralized. ADMM requires 
a multitude of iterations in which estimates for (w,b) are refined using each site’s data. See 
Appendix A for a more detailed description of SVMs and ADMM.
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Learning & validation
For details on additional data processing steps, parametrization of the ADMM algorithm, and 
the code used to execute the algorithm, we refer to Appendix B.
To display the capabilities of the distributed learning network, support vector machines are 
once trained on all sites and once trained and validated in a cross-validation design: the SVM 
is fitted using data from four sites and validated on the remaining site. This process is repeated 
four times with validation on another site. The average values for training and validation 
constitute the cross-validation result.
The models’ performance is measured in terms of discriminative performance expressed as 
the area under the curve (AUC) of the Receiver Operating Characteristic curve (ROC).
To demonstrate the validity of the distributed learning approach with respect to a centralized 
learning algorithm, we compare the ADMM results to solutions from a centralized SVM 
optimizer. To this end, we centralize the data from all sites and solve the SVM optimization 
problem (Eqs. (1)–(3), Appendix A). Missing value imputation is still done per site to ensure 
comparability of centralized and distributed results. For this demonstration, the distributed 
algorithm is run in a local simulation environment.
Results & discussion
The results for learning and validation on all sites and the 5-fold cross-validation can be 
found in Table 2. The discriminative performance in the cross-validation is modest with a 
validation AUC of 0.66 but stable across training (0.62) and validation (0.66). Training AUCs 
are stable across folds (0.60–0.64) while inter-fold validation AUCs vary considerably (0.57–
0.77). Published models12,13 show similar discriminative performance. The sole purpose of the 
presented SVM models is to display the infrastructure’s functionality and it is advised not to 
use these models in a clinical setting.
The coefficients of the SVM trained in the euroCAT network and in centralized learning can 
be found in Table 4. The individual run time of the 6 learning runs in the current euroCAT 
network was approximately 2 h or less with an iteration count between 300 and 500. Fig. 2 
illustrates the convergence of the ADMM results to the centralized optimization results for 
all six learning runs. The iteration number is listed on the x-axis, the norm of the difference 
between ADMM and centralized results is shown on the y-axis. The algorithm was run for 
104 iterations and the iterations in which the internal convergence criteria are met in the 
euroCAT network are indicated by vertical lines. In all six cases, the solution approaches 
the centralized solution non-monotonically until the convergence criteria are met and 
the ADMM algorithm stops. The ADMM-based SVMs do not completely coincide with 
centralized models (see Table 4) as the convergence criteria were relaxed to accommodate 
for the relatively long network communication time in each iteration. A centralized learning 
algorithm determines SVM coefficients in less time as there is no network communication. 
Thus, when using ADMM-based distributed learning (or other distributed learning methods 
with repeating master-site communication), one faces a trade-off between solution precision 
and computation time. While the network communication time will surely force large-
scale simulation studies to be maximally parallelized (to minimize the impact of network 
communication), the impact on prediction model development and performance is expected 
to be limited: the impact on AUC-based discriminative performance is small for the exemplary 
SVM models (compare Tables 2 and 3) and can be further reduced with stricter convergence 
criteria (see Fig. 2). Viewed differently, ‘early stopping’ is employed in machine learning as a 
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regularization technique to avoid overfitting14. Models that suffer from overfitting explain the 
training data but fail to correctly predict outcomes in other datasets. Therefore, the trade-off 
between solution precision and computation time should not harm the goal of developing 
robust machine learning models for personalized medicine.
Figure 2. Convergence graphs of distributed ADMM solutions xd to centralized solutions xc for 10
4 iterations. 
Vertical lines indicate the iterations in which internal convergence criteria were met in the euroCAT network. The 
data was created in local simulations. ‘~’ indicates ‘Trained on all sites except’.
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Table 2. Discrimination performance (AUC) obtained by learning an SVM on all sites and in a 5-fold CV in 
distributed learning (ADMM, following the formulation shown in Eqs. (4)–(7), Appendix A).
CV
Train on All All except Maastricht
All except 
Eindhoven
All except 
Hasselt
All except 
Liège
All except 
Aachen  
Validate on Maastricht Eindhoven Hasselt Liège Aachen  
Training AUC 0.63 0.61 0.60 0.64 0.62 0.64 0.62
Validation AUC 0.58 0.77 0.57 0.72 0.64 0.66
Table 3. Discrimination performance (AUC) obtained by learning an SVM on all sites and in a 5-fold CV in 
centralized learning (solving the optimization problem shown in equations 1-3, Appendix A).
CV
Train on All All except Maastricht
All except 
Eindhoven
All except 
Hasselt
All except 
Liège
All except 
Aachen  
Validate on Maastricht Eindhoven Hasselt Liège Aachen  
Training AUC 0.63 0.61 0.60 0.63 0.61 0.64 0.62
Validation AUC 0.58 0.77 0.59 0.72 0.64 0.66
Table 4. SVM coefficients (w,b) learned by distributed and centralized learning.
Trained on   w1 w2 w3 w4 b
All Distributed 0.01 -0.32 -0.20 -0.25 -0.55
  Centralized 0.01 -0.31 -0.20 -0.25 -0.55
All except Maastricht Distributed -0.03 -0.31 -0.20 -0.29 -0.51
  Centralized -0.02 -0.31 -0.20 -0.29 -0.51
All except Eindhoven Distributed 0.01 -0.28 -0.06 -0.33 -0.48
  Centralized 0.02 -0.28 -0.06 -0.33 -0.48
All except Hasselt Distributed 0.00 -0.32 -0.20 -0.26 -0.55
  Centralized 0.00 -0.31 -0.20 -0.26 -0.55
All except Liège Distributed 0.00 -0.31 -0.20 -0.25 -0.55
  Centralized -0.01 -0.31 -0.20 -0.26 -0.55
All except Aachen Distributed 0.00 -0.34 -0.19 -0.24 -0.53
  Centralized 0.00 -0.34 -0.19 -0.24 -0.53
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A challenge of distributed learning is that the user is not able to inspect the data which is 
used as input for the machine learning applications. S/he must rely on summary statistics to 
ascertain that the data is in the desired format. This obstacle can be overcome by collaboration 
between users from the respective institutes and strictly following the agreed data collection 
and storage protocols. An euroCAT umbrella protocol15 was provided to the participating 
institutes to guide future lung data collection. Protocols for other diseases are also available: 
for a data sharing project between MAASTRO Clinic and the Sacred Heart University Hospital 
(Rome) on rectal cancer, a corresponding umbrella protocol was developed16.
Systematic data sharing not only requires an IT infrastructure, as developed in this study, 
but it also depends on systematic data collection in routine clinical care. It has been argued 
that data from routine care is a valuable source of information to improve the standard of 
care5,17. However, this data is often not treated as such. Consequently, data collection and 
standardization have the potential to be improved as also observed in this study.
Even though routine clinical care might become a cornucopia of clinical data, this data 
needs to be handled with care: McGale et al. (2016)18 show that conclusions from routine 
clinical care data may contradict findings from randomized clinical trials. Routine care data is 
subject to many biases contrary to data from carefully designed trials. The conclusion should 
not be to discard routine care data altogether but rather to develop means to profit from this 
data: i.e., develop appropriate methodology, e.g., extensive correction for confounders19, and 
to expand standardized data collection to capture all data necessary to detect confounders, 
e.g., collect accompanying patient data from referring hospitals/physicians and details on the 
(quality of the) treatment given. Viewed differently, the purpose of data collection, regardless 
whether it is data from randomized clinical trials or routine care, is to improve treatment 
quality for all patients. Peters et al. (2010)20 show that even within clinical trials treatment 
quality is highly variable among institutes, i.e. institutes treating fewer patients delivering 
lower quality treatments. Given these difference, it is debatable whether conclusions drawn 
from trials which were conducted at selected institutes translate into routine clinical care where 
the standard of care may be generally lower and patient populations differ21,22. Data collected 
in routine clinical care is directly sampled from the population in question unlike trial data 
derived from a biased proxy. Therefore, systematic data collection in routine clinical care will 
not only provide new opportunities for further analyses (with the abovementioned necessary 
caution) but it will also allow systematic studies of the general patient population and tracking 
whether treatment benefits observed in clinical trials arrived in routine clinical care.
Continued concerns over patient privacy might render institutes reluctant to participate 
in systematic data sharing. Illegal access to data is prevented within the euroCAT learning 
environment: the web browser-based learning interface is only accessible with registered user 
accounts and learning runs are always linked to such account. Learning algorithms circulating 
in the network need to be authenticated by a digital file signer that is available only to registered 
members of the euroCAT network. Furthermore, permission to learn on an institute’s data is 
granted by the respective institute’s principal investigators per user account or on a run-by-run 
basis. Additionally, illegal data transfers can be identified and shut down: standard master/
site communication is limited to small volumes like model parameters, prediction outcomes, 
and summary statistics. Limits on the communication volume therefore render high volume 
data transfers impossible. Collaboration with external parties always comes with a risk of 
losing control over one’s data. Mutual trust and legal assurance to safeguard other parties’ 
data are key aspects in scientific collaboration. However, in comparison to the traditional 
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data exchange collaborations, a data sharing network such as euroCAT adds technical control 
mechanisms to manage and limit access to an institute’s data.
The pilot study was restricted to sharing a dataset of limited size in three countries. However, 
the range of variables, number of patients, and number of institutes is variable: linking an 
entire hospital’s EHR and PACS to the learning environment is theoretically possible. Further, 
the ontologies used for euroCAT to match variables across institutes bear the potential to 
facilitate data sharing around the globe. For euroCAT, data was shared across clinics located 
in three different countries, i.e. with three different national data collection guidelines and 
three different languages (Dutch, French, and German). This pilot study has led to followup 
projects in, among others, the Netherlands (duCAT), Italy (VATE), the USA (meerCAT), 
Australia (ozCAT), Canada (canCAT), and China (sinoCAT).
The potential of the euroCAT infrastructure exceeds the presented results. The capability 
to learn SVMs is just one example for applications of the distributed learning infrastructure. 
The ADMM algorithm used for SVMs is extendable to other existing machine learning 
methods like linear/logistic regressions and feature selection methods like (logistic) LASSO10. 
Independent of the ADMM algorithm, the infrastructure can facilitate other machine learning 
techniques such as Bayesian Networks learned from distributed data23. More generally, any 
desirable computation requiring access to an institute’s data with subsequent aggregation on 
the master is feasible. Systematic data sharing efforts such as euroCAT will likely profit from 
the ongoing research in the flourishing fields of machine learning and artificial intelligence.
The presented IT infrastructure facilitates modeling of multicentric data without direct access 
to said data. This method bears the risk that inter-institutional bias in variables, e.g., due 
to inconsistent (toxicity) scoring, varying reporting standards, different patient populations, 
or data collection errors remain unnoticed. Future work will be focused on the systematic 
detection of such affected data in a distributed learning network.
Conclusion
Multi-centric rapid learning for health care is feasible as shown by the support vector 
machines developed in the euroCAT network. We have no doubts that the clinical decision 
support systems of the future would routinely use models based on data available in 
distributed databases across national borders. One solution for surmounting accompanying 
technical, legal, and ethical issues with data sharing is already delivered across three countries 
by the euroCAT system and has shown to scale globally. We believe that distributed learning 
is the best way to go for building clinically reliable models that are universally applicable, 
personalized, and robust.
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Appendix A
A support vector machine determines two parallel hyperplanes, forming a ‘border’ which 
separates the feature space into two large regions and a margin between the planes. Each 
dimension of this feature space represents one patient feature (e.g., FEV1 (in %) or cardiac 
comorbidity) and each patient is represented by one point in this space. For simple problems, 
the intention would be to identify hyperplanes that separate all patients with dyspnea from 
the group of patients without dyspnea. This is in not possible in most cases, therefore the 
objective becomes to find hyperplanes such that
• most of the dyspneic patients are on one and non-dyspneic patients are on the other 
side; if there is a patient on the ‘wrong’ side of the border, the distance to the border is 
as small as possible;
• the border between the groups of dyspneic and non-dyspneic patients is as large as 
possible.
The optimal hyperplanes are determined by
min�,�
1
𝜆𝜆 �|𝑤𝑤|��
� 𝑤 � 𝑠𝑠�
�
���
(1) 
� (2) such that 𝑦𝑦�(𝑑𝑑�𝑤𝑤 𝑤 𝑏𝑏) ≥ 1 − 𝑠𝑠  for all 𝑖𝑖 = 1, … , 𝑛𝑛 
𝑠𝑠� ≥ 0  for all 𝑖𝑖  =  1, … , 𝑛𝑛. (3) 
𝑤𝑤 is the normal vector of the separating hyperplanes, 𝑏𝑏 is the bias term. (𝑤𝑤,𝑏𝑏) characterizes 
the hyperplanes. 𝑠𝑠� is an auxiliary variable for sample 𝑖𝑖 representing the classification error. 
𝜆𝜆 is a parameter to assign more importance to the first or the second term of the objective. 𝜆𝜆 
needs to be positive. 𝑦𝑦� ∈ {−1,1} is the label of training sample 𝑖𝑖. 𝑑𝑑� is the vector of features
for sample 𝑖𝑖. Minimizing the first term in the objective function, �� �|𝑤𝑤|��
�
, maximizes in the 
margin, i.e., the space between both hyperplanes. Minimizing ∑ 𝑠𝑠�����  minimizes the 
classification error. The objective is split into two terms, �� �|𝑤𝑤|��
�
 and ∑ 𝑠𝑠����� : The latter is 
𝑥𝑥���� = argmin�� �1�(𝐴𝐴�𝑥𝑥� 𝑤 1)� 𝑤 �
𝜌𝜌
2� �𝑥𝑥� − 𝑧𝑧
� 𝑤 𝑢𝑢����
�� (4) 
𝑥𝑥����� = 𝛼𝛼𝑥𝑥���� 𝑤 (1 − 𝛼𝛼)𝑧𝑧� (5) 
𝑧𝑧��� = 𝜌𝜌
�1𝜆𝜆� 𝑤 𝑁𝑁𝜌𝜌
�𝑥𝑥�̅��� 𝑤 𝑢𝑢��� (6) 
𝑢𝑢���� = 𝑢𝑢�� 𝑤 𝑥𝑥����� − 𝑧𝑧��� (7) 
where 𝑥𝑥 =  (𝑤𝑤, 𝑏𝑏), 𝑁𝑁 is the number of sites, and 𝜌𝜌 and 𝛼𝛼 are model parameters. 
In each iteration 𝑘𝑘 𝑤 1, 𝑥𝑥���� is computed at each site 𝑗𝑗 and transmitted to the master. At the 
master, a relaxation function (5) is applied to 𝑥𝑥���� yielding 𝑥𝑥�����. The average 𝑥𝑥�̅��� of all 
sites is used to compute 𝑧𝑧��� and 𝑢𝑢���, which are transmitted to the sites and are used as 
input for the computation of 𝑥𝑥���� in the next iteration. 𝑥𝑥���� is calculated to reduce the 
�separable among data samples such that the value for   ∑��� 𝑠𝑠�  can be obtained by slicing up
the dataset into multiple parts, computing the contribution of each slice independently and 
merging the results afterwards. This property (and other) can be exploited such that the 
SVM optimization problem is solvable in a distributed fashion. Boyd et al.(2011)10 discuss a 
distributed formulation of a support vector machine using the Alternating Direction 
Method of Multipliers and provide MATLAB code11. The ADMM algorithm gained 
popularity in the machine learning community as it allows to split up large datasets into 
smaller portions and distribute the analysis over multiple machines. In our multi-centric 
learning context, the same property is exploited to overcome the restriction that data may 
not be centralized. The formulation is 
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where 𝑥𝑥 =  (𝑤𝑤, 𝑏𝑏), 𝑁𝑁 is the number of sites, and 𝜌𝜌 and 𝛼𝛼 are model parameters. 
In each iteration 𝑘𝑘 𝑤 1, 𝑥𝑥���� is computed at each site 𝑗𝑗 and transmitted to the master. At the 
master, a relaxation function (5) is applied to 𝑥𝑥���� yielding 𝑥𝑥�����. The average 𝑥𝑥�̅��� of all 
sites is used to compute 𝑧𝑧��� and 𝑢𝑢���, which are transmitted to the sites and are used as 
input for the computation of 𝑥𝑥���� in the next iteration. 𝑥𝑥���� is calculated to reduce the 
�separable among data samples such that the value for   ∑��� 𝑠𝑠�  can be obtained by slicing up
the dataset into multiple parts, computing the contribution of each slice independently and 
merging the results afterwards. This property (and other) can be exploited such that the 
SVM optimization problem is solvable in a distributed fashion. Boyd et al.(2011)10 discuss a 
distributed formulation of a support vector machine using the Alternating Direction 
Method of Multipliers and provide MATLAB code11. The ADMM algorithm gained 
popularity in the machine learning community as it allows to split up large datasets into 
smaller portions and distribute the analysis over multiple machines. In our multi-centric 
learning context, the same property is exploited to overcome the restriction that data may 
not be centralized. The formulation is 
where x = (w,b), N is the nu ber of sites, and p and α are model parameters. 
In each iteration k + 1, xjk+1 is computed at each site j and transmitted to the master. At the 
master, a relaxation function (5) is applied to xjk+1 yielding x̂jk+1.The average x ̂̅ k+1 of all sites is 
used to compute zk+1 and uk+1, which are transmitted to the sites and are used as input for the 
computation of xjk+2 in the next iteration. xjk+1 is calculated to reduce the classification error, 
zk+1 is calculated to increase the margin, and ujk+1 is the dual variable inherent to the ADMM 
algorithm. ADMM requires a multitude of iterations in which estimates for (w,b) are refined 
using each site’s data. Once an estimate of (w,b) is chosen and the algorithm is stopped, Platt 
scaling24 is applied: the values di w+b per training sample i are fitted to the dyspnea outcomes 
using a logistic regression. di w+b is a measure of training sample i’s location in space relative 
to the two hyperplanes. The logistic regression equation allows to assign a dyspnea probability 
to patients in the training and validation datasets.
Appendix B
Data processing was done in MATLAB (MathWorks, Natick, MA, USA). Pseudocodes of the 
MATLAB functions executed on the master and sites are shown in Figs. B1 and B2, respectively. 
Patient features were rescaled before learning to improve algorithm performance. A variable v 
was rescaled to ṽ according to
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where 𝑥𝑥𝑥𝑥 =  (𝑑𝑑𝑑𝑑, 𝑏𝑏𝑏𝑏), 𝑁𝑁𝑁𝑁 is the number of sites, and 𝜌𝜌𝜌𝜌 and 𝛼𝛼𝛼𝛼 are model parameters. 
In each iteration 𝑘𝑘𝑘𝑘 + 1, 𝑥𝑥𝑥𝑥𝑗𝑗𝑗𝑗𝑘𝑘𝑘𝑘+1 is computed at each site 𝑗𝑗𝑗𝑗 and transmitted to the master. At the 
master, a relaxation function (5) is applied to 𝑥𝑥𝑥𝑥𝑗𝑗𝑗𝑗𝑘𝑘𝑘𝑘+1 yielding 𝑥𝑥𝑥𝑥�𝑗𝑗𝑗𝑗𝑘𝑘𝑘𝑘+1. The average 𝑥𝑥𝑥𝑥�̅𝑘𝑘𝑘𝑘+1 of all sites is used 
to compute 𝑧𝑧𝑧𝑧𝑘𝑘𝑘𝑘+1 and 𝑢𝑢𝑢𝑢𝑘𝑘𝑘𝑘+1, which are transmitted to the sites and are used as input for the 
computation of 𝑥𝑥𝑥𝑥𝑗𝑗𝑗𝑗𝑘𝑘𝑘𝑘+2 in the next it ration. 𝑥𝑥𝑥𝑥𝑗𝑗𝑗𝑗𝑘𝑘𝑘𝑘+1 is calcul ted to reduce the cl ssification error, 𝑧𝑧𝑧𝑧𝑘𝑘𝑘𝑘+1 
is calculated to increase the margin, and 𝑢𝑢𝑢𝑢𝑗𝑗𝑗𝑗𝑘𝑘𝑘𝑘+1 is the dual variable inherent to the ADMM algorithm. 
ADMM requires a multitude of iterations in which estimates for (𝑑𝑑𝑑𝑑, 𝑏𝑏𝑏𝑏) are refined using each site’s 
data. Once an estimate of (𝑑𝑑𝑑𝑑, 𝑏𝑏𝑏𝑏) is chosen and the algorithm is stopped, Platt scaling [24] is applied: 
the values 𝑑𝑑𝑑𝑑𝑖𝑖𝑖𝑖𝑑𝑑𝑑𝑑 + 𝑏𝑏𝑏𝑏 per training sample 𝑖𝑖𝑖𝑖 are fitted to the dyspnea outcomes usi g a logistic 
regressi n. 𝑑𝑑𝑑𝑑𝑖𝑖𝑖𝑖𝑑𝑑𝑑𝑑 + 𝑏𝑏𝑏𝑏 is a measure of training sample 𝑖𝑖𝑖𝑖’s location in space relative to the two 
hyperplanes. The logistic regression equation allows to assign a dyspnea probability to patients in the 
training and validation datasets. 
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Data processing was done in MATLAB (MathWorks, Natick, MA, USA). Pseudocodes of the MATLAB 
functions xecuted on the master and sites are shown in Figs. B1 and B2, respectively. Patient 
features were rescaled before learning to improve algorithm performance. A variable 𝑣𝑣𝑣𝑣 was rescaled 
to 𝑣𝑣𝑣𝑣� according to 
 
𝑣𝑣𝑣𝑣� = 𝑣𝑣𝑣𝑣 − min (𝑣𝑣𝑣𝑣)max(𝑣𝑣𝑣𝑣) − min (𝑣𝑣𝑣𝑣) 
 
where min (𝑣𝑣𝑣𝑣) and max (𝑣𝑣𝑣𝑣) are minimal and maximal feature values, respectively, found within the 
entire learning network. This step requires centralizing minimal and maximal feature values for each 
site. This poses no threat to patient privacy since no value can be allocated to a single patient 
assuming that each site’s database contains more than one patient. Future work should be dedicated 
to replacing this normalization by a generally privacy-preserving method. 
The categorical variables cardiac comorbidity and chemotherapy timing were each coded as (𝑐𝑐𝑐𝑐 − 1) 
dummy variables, 𝑐𝑐𝑐𝑐 being equal to the variable’s cardinality. 
Missing values were imputed using the mean for continuous variables and mode for categorical 
variables. Means and modes were derived per site. 
The code designed to guide the machine learning process within the IT infrastructure is available on 
www.eurocat.info with further information about the infrastructure and how to join the CAT project. 
The chosen model parameters are 𝜌𝜌𝜌𝜌 = 1, 𝛼𝛼𝛼𝛼 = 1.5, and 𝜆𝜆𝜆𝜆 = 0.01. The convergence criteria are set as 
described by [11] with absolute tolerance = 10−4 and relative tolerance = 10−2. 𝑥𝑥𝑥𝑥, 𝑧𝑧𝑧𝑧, and 𝑢𝑢𝑢𝑢 are 
initialized at the zero vector. Parameters have been set manually and based on choices found in [11]. 
Future work on deriving clinically-relevant prediction models exceeding an exemplary nature should 
also comprise systematic parameter tuning. 
where min (v) and max (v) are minimal and maximal feature values, respectively, found within 
the entire learning network. This step requires centralizing minimal and maximal feature 
values for each site. This poses no threat to patient privacy since no value can be allocated 
to a single patient assuming that each site’s database contains more than one patient. Future 
work should be dedicated to replacing this normalization by a generally privacy-preserving 
method.
The categoric l variables ardiac comorbidity and chemotherapy timing were each coded as 
(c-1) dummy variables, c being equal to the variable’s cardinality.
Missing values were imputed using the mean for continuous variables and mode for categorical 
variables. Means and modes were derived per site.
The code designed to guide the machine learning process within the IT infrastructure is 
available on www.eurocat.info with further information about the infrastructure and how to 
join the CAT project.
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The chosen model parameters are ρ=1, α=1.5, and λ=0.01. The convergence criteria are set 
as described by11 with absolute tolerance = 10-4 and relative tolerance = 10-2. x, z, and u are 
initialized at the zero vector. Parameters have been set manually and based on choices found 
in11. Future work on deriving clinically-relevant prediction models exceeding an exemplary 
nature should also comprise systematic parameter tuning. Figure B.1. Pseudocode of the MATLAB function executed on the master. 
Figure B.2. Pseudocode of the MATLAB function executed on the sites. 
read user input file 
IF in first iteration 
    assign master and sites to 'data reading' stage 
    create input files for sites 
ELSE 
    read site output files 
    IF in 'data reading' stage 
assign master and sites to 'learning' stage 
compute min. and max. values per variable over all sites 
assign min. and max. values as input for sites 
create input files for sites 
    ELSEIF in 'learning' stage 
compute 𝑧𝑧𝑧𝑧- and 𝑢𝑢𝑢𝑢-updates 
check convergence criteria 
IF optimization has converged OR iteration limit is reached 
assign master and sites to 'evaluation' stage 
set final model as mean of 𝑥𝑥𝑥𝑥 over all sites     
assign 𝑥𝑥𝑥𝑥𝑥 as input for sites 
END 
create input files for sites 
    ELSEIF in 'evaluation' stage 
fit logistic regression to 𝑑𝑑𝑑𝑑𝑖𝑖𝑖𝑖𝑑𝑑𝑑𝑑 + 𝑏𝑏𝑏𝑏 and 𝑦𝑦𝑦𝑦𝑖𝑖𝑖𝑖 for all training site samples 𝑖𝑖𝑖𝑖 
compute regression estimates for all training and validation site samples 
write regression estimates and 𝑦𝑦𝑦𝑦 to result file 
    END 
END
read master output file 
IF in 'data reading' stage 
    read data from site 
    compute min. and max. values per variable 
    assign min. and max. values as input for master 
ELSEIF in 'learning' stage 
    IF processed data file exists 
read processed data file 
    ELSE 
  read data from site 
impute missing data 
dummy code categorical data 
rescale data using min. and max. values provided by master 
write processed data to file  
    END 
    IF this is a training site 
compute 𝑥𝑥𝑥𝑥-update 
    END 
ELSEIF in 'evaluation' stage 
    read processed data file 
    compute 𝑑𝑑𝑑𝑑𝑖𝑖𝑖𝑖𝑑𝑑𝑑𝑑 + 𝑏𝑏𝑏𝑏 for each sample 𝑖𝑖𝑖𝑖 
    assign the pairs (𝑑𝑑𝑑𝑑𝑖𝑖𝑖𝑖𝑑𝑑𝑑𝑑 + 𝑏𝑏𝑏𝑏,𝑦𝑦𝑦𝑦𝑖𝑖𝑖𝑖) for each sample 𝑖𝑖𝑖𝑖 as input for master 
END 
create input file for master
Figure B.1. Pseudocode of the MATLAB function executed on the master.
 Figure B.1. Pseudocode of the MATLAB function executed on the master. 
Fi ure B.2. Pseudocode of the MATLAB function executed on the sites. 
read user input file 
IF in first iteration 
    assign master and sites to 'data reading' stage 
    create input files for sites 
ELSE 
    read site output files 
    IF in 'data reading' stage 
assign master and sites to 'learning' stage 
compute min. and max. values per variable over all sites 
assign min. and max. values as input for sites 
create input files for sites 
    ELSEIF in 'learning' stage 
compute 𝑧𝑧𝑧𝑧- and 𝑢𝑢𝑢𝑢-updates 
check convergence criteria 
IF optimization has converged OR iteration limit is reached 
assign master and sites to 'evaluation' stage 
set final model as mean of 𝑥𝑥𝑥𝑥 over all sites     
assign 𝑥𝑥𝑥𝑥𝑥 as input for sites 
END 
create input files for sites 
    ELSEIF in 'evaluation' stage 
fit logistic regression to 𝑑𝑑𝑑𝑑𝑖𝑖𝑖𝑖𝑑𝑑𝑑𝑑 + 𝑏𝑏𝑏𝑏 and 𝑦𝑦𝑦𝑦𝑖𝑖𝑖𝑖 for all training site samples 𝑖𝑖𝑖𝑖 
compute regression estimates for all training and validation site samples 
write regression estimates and 𝑦𝑦𝑦𝑦 to result file 
    END 
END
read master output file 
IF in 'data reading' stage 
    read data from site 
    compute min. and max. values per variable 
    assign min. and max. values as input for master 
ELSEIF in 'learning' stage 
    IF processed data file exists 
read processed data file 
    ELSE 
  read data from site 
impute missing data 
dummy code categorical data 
rescale data using min. and max. values provided by master 
write processed data to file  
    END 
    IF this is a training site 
compute 𝑥𝑥𝑥𝑥-update 
    END 
ELSEIF in 'evaluation' stage 
    read processed data file 
    compute 𝑑𝑑𝑑𝑑𝑖𝑖𝑖𝑖𝑑𝑑𝑑𝑑 + 𝑏𝑏𝑏𝑏 for each sample 𝑖𝑖𝑖𝑖 
    assign the pairs (𝑑𝑑𝑑𝑑𝑖𝑖𝑖𝑖𝑑𝑑𝑑𝑑 + 𝑏𝑏𝑏𝑏,𝑦𝑦𝑦𝑦𝑖𝑖𝑖𝑖) for each sample 𝑖𝑖𝑖𝑖 as input for master 
END 
create input file for master
Figure B.2. Pseudocode of the MATLAB function executed on the sites.
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Abstract
Access to healthcare data is indispensable for scientific progress and technological 
innovation. Sharing healthcare data is time-consuming and notoriously difficult due to 
privacy and regulatory concerns. The Personal Health Train provides a privacy-by-design 
infrastructure connecting FAIR (Findable, Accessible, Interoperable, Reusable) data sources 
and allows distributed data analysis and machine learning. Patient-specific data never leaves a 
healthcare provider. We present results of the Personal Health Train’s application across eight 
international healthcare institutes (Amsterdam, Cardiff, Maastricht, Manchester, Nijmegen, 
Rome, Rotterdam, Shanghai): a study executed and analyzed in only 4 months. We trained and 
validated a distributed logistic regression model predicting post-treatment two-year survival 
in 23 203 non-small cell lung cancer patients treated between 1978-2015 based on tumor 
staging definitions established by the American Joint Committee on Cancer. The Personal 
Health Train infrastructure demonstrably overcomes patient-privacy barriers to healthcare 
data sharing and promotes global evidence-based medicine. 
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Many current innovations in medicine, including personalized medicine, artificial intelligence, 
(big) data-driven medicine, learning healthcare systems, value-based healthcare and decision 
support systems, rely on the sharing of data across healthcare providers. Conventional data 
analysis requires sharing and centralization of data to answer research questions. However, 
data sharing is hampered by administrative, political, ethical, and technical barriers1. This 
limits the amount of healthcare data available for life sciences in general as well as for other 
secondary uses such as healthcare quality assurance.
Distributed (machine) learning reformulates conventional data analysis algorithms so that 
data centralization becomes unnecessary. Distributed algorithms iteratively analyze separate 
databases and return the same solution as if data were centralized: essentially sharing research 
questions and answers between databases instead of data.
We are convinced that only sharing research questions (and answers) between healthcare 
providers is a better, sustainable approach to medical data analysis, and can unlock orders 
of magnitude more data without violating privacy. To this end, we have developed an 
infrastructure called the Personal Health Train2 (PHT) consisting of
• sites (“stations”) containing FAIR3 (Findable, Accessible, Interoperable, Reusable) data,
• technical network connections and legal frameworks (“tracks”),
• statistical learning applications (“trains”).
A global community of likeminded healthcare providers and academic partners called 
CORAL (Community in Oncology for RApid Learning) was initiated at the 2016 European 
Society for Radiotherapy and Oncology (ESTRO) conference. In various research projects 
across the globe, CORAL members have worked on the realization of the PHT.
An infrastructure to bring research questions to the data has been demonstrated to work 
recently in projects such as euroCAT4,5, DataSHIELD6 and OHDSI7. However, challenges 
remain in terms of the number of data subjects, number of data providers, and global coverage.
The aim of this study is to show that the PHT distributed learning infrastructure can be 
scaled to many thousands of patients, approaching the size of national healthcare registries. 
Specifically, we set the goal (as registered on clinicaltrials.gov8) to machine learn a predictive 
model for post-treatment two-year survival on more than 20 000 non-small cell lung cancer 
(NSCLC) patients, in at least five healthcare providers from more than five countries—without 
any patient data leaving a healthcare provider.
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Results
In total, eight healthcare providers (“stations”) were contacted on 18-06-2018 and two 
additional sites were contacted later. At the deadline of 01-09-2018 (71 days after the first 
formal project invitation), eight sites (in Amsterdam, Cardiff, Maastricht, Manchester, 
Nijmegen, Rome, Rotterdam, Shanghai) made NSCLC patient data available in their local 
database endpoints and two sites did not participate for logistical reasons: delayed response 
to first formal invitation in one case and too little time to participate after a second round of 
invitations in another case. NSCLC patient data consists of two-year survival information
• diagnosis,
• diagnosis date,
• survival follow-up status,
• survival follow-up status date,
and cancer staging as defined by the American Joint Committee on Cancer (AJCC, see 
Methods for details)
• tumor (T) stage,
• lymph node (N) stage,
• metastasis (M) stage,
• overall disease stage.
Data availability
A summary statistics application (“train”) was sent via the Varian Learning Portal (“track”). It 
computed patient counts for each variable category, displayed in Table 1. Each site confirmed 
the validity of the summary statistics, a quality control step to ensure that correct data was 
used for modelling. A total number of 37 090 patients became available in the system. When 
restricting the search to patients:
• diagnosed or treated from 01-01-1978 (effective date of the AJCC TNM cancer staging 
edition 1) and before 01-01-2016 (allowing at least two years survival follow-up),
• with complete diagnosis date, follow-up date, and follow-up status (to calculate two-year 
survival),
the number of available patients decreased to 28 178, which forms the modelling cohort. Data of 
patients diagnosed before 2005 were mainly collected by two sites (with minor contributions 
from two other sites). Data of patients diagnosed after 2005 were made available by all sites. 
Overall, recent data was more abundant. More than half of the modelling data was provided 
by two sites: site G (43.0%) and site E (17.0%). Less than 6% of the modelling data was sourced 
from three sites: site D (2.4%), site C (2.3%), and site B (1.0%).
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Modelling cohort distribution
Histograms for T, N, M, and overall stage categories after binning into supercategories (Table 6) 
but before imputation are shown in Figure 1. Patients with missing or right-censored two-year 
survival are excluded. The histograms are separate per site (x-axis) and split for patients alive 
and dead at two years after diagnosis (above and below x-axis). Patient counts are normalized 
per site. Sites are ordered by the percentage of patients alive at two years.
The percentage of patients alive at two years differed greatly in the provided data across 
sites (Figure 1): from 89.1% in site A to 18.8% in site H. The distribution of T, N, M, and 
overall stage categories also varied across sites. Notably, T1 clearly dominated in sites A and 
C but other sites display a more balanced distribution of T categories (Figure 1a). In sites 
A-E, N0 is the modal lymph node category but N2 is most frequent in sites F-H (Figure 1b). 
All sites report most patients in the M0 category but the decrease in M0 patients correlates 
loosely with the percentage of patients alive at two years per site, e.g., site H reports 41.4% 
M1 compared to 8.8% in site A (Figure 1c). As a direct consequence of the differences in T, 
N, and M category distributions, the overall stage distribution varies across sites (Figure 1d).
In general, data completeness is not consistent in the network (Table 1). Sufficient follow-
up information to compute two-year survival ranges from 92.1% (site D) to 44.1% (site B). 
Note that patients with incomplete follow-up (right-censored) have not been included in the 
modelling cohort displayed in Figure 1 and Figure 2. T, N, M, or overall stage information 
is frequently missing in half of the sites (sites E-H). Overall stage categories are not always 
reported: sites E and H do not provide overall stage information. Sites G, F, and A miss it for 
39.8%, 31.8%, and 2.2% of their patients, respectively.
Distributed machine learning
Based on the temporal distribution of patients in the modelling cohort, we selected patients 
from 01-01-1978 until and including 31-12-2011 for training and patients from 01-01-2012 
until and including 31-12-2015 for validation so that we achieved a split of approximately 2/3 
to 1/3. We selected a temporal split for training and validation (TRIPOD type 2b validation9) to 
simulate the development of the model on historical patient data and subsequent application 
in future patients.
Only 14 660 patients of 28 178 patients were complete cases (T, N, M, overall stage, and 
two-year survival) in the modelling cohort (Table 3). Missing T, N, M and overall stage were 
imputed using logical rules according to the AJCC TNM cancer staging editions and observed 
patient frequencies in the respective site. Imputation did not result in complete cases for 
a subset of patients (see methods section for details) yielding 14 810 (63.8%) patients for 
training and 8 393 (36.2%) patients for validation, a total of 23 203 patients.
The logistic regression application trained a model from the training data (years 1978-2011) 
with coefficients as displayed in Table 2. The convergence criteria of the algorithm are met 
after 81 iterations (25 minutes). The convergence of the algorithm is displayed in Figure 2b: 
the root mean square error (RMSE) for predicting the probability of two-year survival (left 
y-axis) in the training cohort decreases per iteration and approaches 0.42. Although the 
RMSE has stabilized, not all regression coefficients (right y-axis) have converged.
The validation application assessed the model’s performance on the validation cohort 
(years 2012-2015). The validation performance is described by the combined RMSE for 
patients from all sites (Figure 2b), the receiver operating characteristic (ROC) curve per site 
and their corresponding areas under the curve (AUCs) (Figure 2c), and by an exemplary 
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calibration plot of the site with most patient data provided for training and validation (site 
G, Figure 2d). Calibration plots for all other sites are displayed in Figure S1 (Supplementary 
Information). Table 3 summarizes patient counts (available in the system and in the modelling 
cohort before and after imputation) and model performance per site. The validation RMSE 
almost-monotonically decreases during optimization on the training cohort. Discriminative 
performance of the model (as measured by the AUC), varies across sites from 0.85 (site A) 
to 0.58 (site D). Model calibration in site G is good with a calibration-in-the-large of 0.02 
and calibration-slope of 0.75 but calibration varies strongly across sites. For example, site 
A (Supplementary Information, Figure S1) displays a calibration-in-the-large of 2.39 and a 
calibration slope of 1.09.
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Table 1. Summary statistics of all patients provided by the sites. These are patient counts before filtering for the 
modelling cohort (diagnosed in 1978-2015 with available two-year survival data and at least one stage variable) and 
before imputation.
Site 
A
Site  
B
Site 
C
Site 
D
Site  
E
Site  
F
Site  
G
Site 
H
Site  
A
Site 
B
Site 
C
Site 
D
Site  
E
Site  
F
Site 
G
Site 
H
Disease Overall stage
NSCLC 5214 706 829 785 6211 4110 16260 2975 Missing 92 3 0 0 6211 1714 7573 2975
T stage 0 208 0 0 0 0 0 1 0
Missing 4 20 0 0 77 807 6703 10 I 0 0 0 0 0 152 282 0
T0 6 1 0 2 3 36 1 16 IA 2413 93 0 141 0 31 704 0
T1 650 30 34 74 322 429 674 200 IA1 0 0 35 0 0 0 6 0
T1a 1694 82 35 42 337 56 351 78 IA2 0 0 191 0 0 0 36 0
T1b 588 40 191 88 285 96 313 117 IA3 0 0 185 0 0 0 31 0
T1c 0 1 185 0 15 16 73 16 IB 501 48 104 141 0 56 373 0
T2 110 75 39 128 1079 803 2138 844 II 0 0 0 0 0 75 101 0
T2a 1032 92 104 139 772 132 472 91 IIA 459 13 49 65 0 17 135 0
T2b 206 18 49 50 194 65 227 45 IIB 188 56 39 78 0 56 235 0
T3 303 165 77 109 1460 523 1936 518 III 0 0 0 2 0 52 621 0
T4 254 151 107 143 1667 1037 1932 639 IIIA 786 187 110 215 0 348 1689 0
TX 164 31 8 10 0 108 1439 396 IIIB 104 103 116 103 0 577 1753 0
Tis 203 0 0 0 0 2 1 5 IIIC 0 0 0 1 0 1 18 0
N stage IV 199 198 0 39 0 1012 2553 0
Missing 0 20 0 0 14 821 6705 7 IVA 75 0 0 0 0 4 54 0
N0 3649 255 637 384 2756 1041 2830 660 IVB 189 5 0 0 0 15 95 0
N1 520 49 13 153 635 208 598 180 Diagnosis year
N2 777 271 143 215 1835 1132 3510 977 1950-1959 0 0 0 0 0 0 1 0
N3 141 83 36 23 971 810 1437 600 1960-1969 0 0 0 0 0 0 2 0
NX 127 28 0 10 0 98 1180 551 1970-1979 0 0 0 0 0 0 693 1
M stage 1980-1989 0 0 0 0 0 3 2301 362
Missing 2 3 0 0 0 554 6705 4 1990-1999 0 2 0 0 1 16 3192 809
M0 4742 491 829 734 4799 2073 6435 1526 2000-2004 0 5 0 8 1 74 1527 421
M1 87 70 0 8 650 1253 1926 1053 2005 0 18 12 51 223 185 374 83
M1a 92 7 0 11 246 36 164 19 2006 0 15 31 50 313 248 365 78
M1b 285 121 0 20 510 124 497 107 2007 1 24 44 59 276 275 506 68
M1c 1 5 0 0 6 15 107 29 2008 190 123 48 51 314 282 498 95
MX 5 9 0 12 0 55 426 237 2009 214 127 71 42 348 317 528 99
2-year survival 2010 318 92 100 62 401 338 541 125
Missing/
Right-
censored
614 395 164 62 692 818 3412 477 2011 445 33 117 77 455 306 554 120
No 464 112 258 396 3834 2305 9357 2048 2012 557 32 112 78 626 300 603 121
Yes 4136 199 407 327 1685 987 3491 450 2013 690 34 97 75 692 369 697 100
2014 971 52 31 70 573 345 755 110
2015 1057 43 62 63 641 300 763 112
2016 761 37 103 58 666 302 744 136
2017 0 35 1 41 562 308 607 112
2018 10 11 0 0 118 142 163 23
40 DISTRIBUTED LEARNING ON 20 000+ LUNG CANCER PATIENTS 
 
 
Figure 1. D
istributions of T, N
, M
, and overall stage supercategories (a, b, c, d, respectively) for patients available for training or validation per site (i.e. the m
odelling cohort) 
before selecting for com
plete cases and im
putation. Patients w
ith m
issing or right-censored tw
o-year survival are excluded. Th
e histogram
s are separate per site (x-axis) and split 
for patients alive and dead at tw
o years after diagnosis (above and below
 x-axis). Patient counts are norm
alized per site. Th
e vertical position of the entire bar indicates the tw
o-year 
survival ratio of each site.
(a)
(c)
(d)
(b)
DISTRIBUTED LEARNING ON 20 000+ LUNG CANCER PATIENTS 41
3
 
 
(a)
(c)
(d)
(b)
Figure 2. (a) Th
e num
ber of patients available for training or validation per year per site. (b) Left axis: root m
ean square error (RM
SE) of logistic regression m
odels optim
ized on the 
training cohort at a given iteration for training and validation cohorts. Right axis: regression coeffi
cients for T, N
, M
, and overall stage categories com
puted by the A
D
M
M
 algorithm
 
at a given iteration. (c) Receiver operating characteristic curves w
ith area under the curve (AU
C) values for the validation cohort per site. (d) Calibration plot of the validation 
cohort for site G
, the site w
ith m
ost training and validation data. Calibration plots for the rem
aining sites are displayed in Figure S1.
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Table 2. Logistic regression coeffi
cients per supercategory. T1N
0M
0 and overall stage category I is the reference case.
Intercept
T
N
M
O
verall stage
0.93
0
0.96
0
ref.
0
ref.
0
1.05
 
1
ref.
1
-0.01
1
-1.09
I
ref.
 
2
-0.69
2
-0.19
X
0.00
II
-0.19
 
3
-1.08
3
-0.67
 
 
III
-0.76
 
4
-0.87
X
-0.54
 
 
IV
-0.82
 
X
-1.22
 
 
 
 
O
ccult
0.37
Table 3. Patient counts and m
odel perform
ance per site. Sites E and H
 are listed as incom
plete as neither site published overall staging data (w
hich m
ay be im
puted from
 T, N
 and 
M
 stages). AU
C: area under the receiver operating characteristic curve. CI: confidence interval.
Site
Available 
patients
M
odelling cohort patient counts (com
plete cases, 1978-2015)
M
odel perform
ance
Before im
putation
A
fter im
putation
Training
Validation
Training
Validation
Total
Training
Validation
Total
AU
C
95%
-CI
AU
C
95%
-CI
Calibration-
in-the-large
Calibration 
slope
Site A
5214
1050
3024
4074
1084
3058
4142
0.79
[0.75, 0.82]
0.85
[0.83, 0.87]
2.39
1.09
Site B
706
203
87
290
204
87
291
0.71
[0.62, 0.77]
0.67
[0.54, 0.78]
1.04
0.62
Site C
829
390
260
650
390
260
650
0.62
[0.57, 0.67]
0.63
[0.57, 0.69]
0.36
0.59
Site D
785
398
276
674
398
276
674
0.61
[0.55, 0.66]
0.58
[0.51, 0.64]
0.07
0.40
Site E
6211
0
0
0
2265
2458
4723
0.70
[0.68, 0.72]
0.73
[0.70, 0.75]
-0.09
0.85
Site F
4110
1165
520
1685
1906
1017
2923
0.73
[0.71, 0.76]
0.74
[0.71, 0.77]
0.20
0.96
Site G
16260
6414
873
7287
6803
889
7692
0.74
[0.73, 0.75]
0.71
[0.68, 0.75]
0.02
0.75
Site H
2975
0
0
0
1760
348
2108
0.74
[0.71, 0.77]
0.75
[0.68, 0.80]
-0.43
0.76
Total
37090
9620
5040
14660
14810
8393
23203
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Discussion
We trained a distributed logistic regression model on 14 810 NSCLC patients and validated it 
on 8 393 patients from eight sites worldwide, yielding a total of 23 203 patients. While we thus 
easily exceeded the goal of 20 000 by 16.0%, the eight participating sites originate from only 
five countries which is one country short of the intended goal.
Applying FAIR principles in this project highlighted the challenges in introducing modern 
data storage and processing approaches in a clinical research context. Semantic web 
technology allows concepts and relationships between concepts to be coded which makes 
data more interpretable – an important FAIR principle. The use of semantic web technology 
requires expertise that is often not present at healthcare institutes. In this project, we worked 
closely with all partners to support installations. Future projects would benefit from user-
friendly software assisting healthcare institutes in transforming their data according to FAIR 
principles. Creating such software is the goal of an ongoing research project in the CORAL 
community.
We observed heterogeneity in modelled variables (T, N, M, and overall stage) and outcome 
(two-year survival) between sites. Sites provided different cohort types, either (complete) 
clinical records of heterogeneous NSCLC cases or study cohorts with narrower inclusion 
criteria which can explain much of this heterogeneity (Table 4). Specifically, site A had 
a biased inclusion towards surviving patients (89.1% two-year survival, Figure 1) and site 
C provided study cohorts. For both sites, these biases skewed T, N, M, and overall stage 
distributions towards lower stages. Even for sites providing data based on their full clinical 
records, different model variable distributions are not surprising since healthcare providers 
treat different patient subgroups. For example, data in site F originates from a radiotherapy 
clinic while the data in site G is provided by a comprehensive cancer care center offering 
different treatments (surgery, (chemo-)radiotherapy, etc.).
For differences in model outcome (two-year survival), there are multiple (possible) 
causes. For example, site A experienced a biased collection of survival information due to 
its unavailability in the healthcare provider’s Electronic Medical Records (EMR) and the 
difficulty of retrospectively gathering this missing information when there is no access to 
survival registries. Furthermore, some sites contributed historical data dating back to 1978 
where treatment outcomes were generally worse. Additionally, treatment choices for patient 
subgroups differ due to national and local treatment guidelines. Another explanation is the 
difference in patient subgroups admitted for treatment with possibly worse prognosis, e.g., 
patients with metastasized NSCLC.
Heterogeneity throughout the network is generally advantageous for prediction modelling 
as it allows models to be trained that are generalizable to a wider range of patients. On the 
other hand, if the difference in cohorts is caused by characteristics not considered by the 
model, e.g., difference in treatments or data collection biases, then these differences can have 
a negative effect on model performance. In our study, site A suffered from a biased inclusion 
of surviving patients. The effect on the trained model should be low as site A only contributed 
7.3% of the training cohort (Figure 2a). However, the usefulness of this dataset for model 
validation is limited because the performance of this model has not been evaluated for the 
entire patient population of the site but only for the subgroup following the biased collection 
(long survivors or recent patients, Table 4). A further inclusion bias is present in site C which 
provided two study cohorts (predominantly overall stage I and III) for training and validation. 
Care has to be taken when interpreting validation results: one can only draw conclusions for 
the patient subpopulation from which the validation dataset has been sampled.
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Inter-comparison of summary statistics between sites highlights significant differences 
in variable distributions that can then be investigated to assure data quality. For example, 
earlier in this study, the N stage statistics showed one site to have an excess of N3 incidence as 
compared to other sites. This was subsequently investigated and uncovered a processing error 
at that site. This role will become increasingly important as outcome modelling studies move 
away from curated clinical trial datasets and towards routinely collected data and structured 
information retrospectively extracted from clinical notes.
We also observed varying model performance between sites: the validation cohort AUCs 
ranged from 0.58 (site D) to 0.85 (site A) and calibration plots (Supplementary Information, 
Figure S1) display obvious differences. Multiple factors might influence stable performance 
across sites: e.g., the aforementioned heterogeneity due to unobserved but important variables, 
or different staging practices across sites. Methods to detect and analyze these discrepancies 
are yet to be developed. Future work can take advantage of the large patient numbers in the 
network to analyze subgroups of similar patients to generate better performing models. The 
Personal Health Train infrastructure provides the means to conduct such analyses.
We observe that our results are qualitatively in accordance with the AJCC TNM cancer 
staging system: the regression coefficients of the presented model (Table 2) indicate decreased 
survival probabilities for increases in T, N, M, and overall stage supercategories (with exception 
of T4). For example, the regression coefficients for overall stage supercategories decrease 
from 1.05 for overall stage category 0 to -0.82 for overall stage category IV. Additionally, we 
quantitatively compared the presented model to the AJCC TNM cancer staging system: we 
retrieved two-year survival probabilities for the overall stages IA, IB, IIA, IIB, IIIA, IIIB, IV 
of the AJCC TNM cancer staging edition 710 (which is the effective edition of the validation 
cohort) and predicted two-year survival in the validation cohort. Patients with overall stages 
other than IA, IB, IIA, IIB, IIIA, IIIB, IV were excluded because these stages are either not 
defined or survival probabilities are not reported in TNM edition 7. AUCs of the presented 
model and the AJCC TNM cancer staging edition 7 coincided (Supplementary Information, 
Table S1).
Published NSCLC two-year survival prediction models report AUCs of, for example, 0.68-
0.7711,12. Comparing the presented model’s performance with published models is difficult for 
multiple reasons:
• inclusion criteria: patient inclusion is restricted to treatment with curative intent12 or 
different treatment techniques13;
• methodology: Cox regression models14–16 or early mortality17 predictions are not directly 
comparable to two-year survival predictions;
• performance estimates: sizes of validation cohorts vary across studies, causing different 
degrees of variability in the performance estimates, therefore rendering comparison 
unreliable.
The presented model is trained and validated on patients exhibiting all NSCLC stages, 
including stage IV patients who are generally not treated with curative intent, have the worst 
prognosis, and are least likely to survive two years after diagnosis (the two-year survival 
probability is approximately 10% according to the seventh edition AJCC TNM cancer staging 
manual10). Their bad prognosis is easily predicted but published studies mostly do not include 
stage IV NSCLC patients. Therefore, the presented model’s estimated two-year survival 
prediction performance is expected to be higher than for published models.
For this project, we have implemented logistic regression, a tool popular in statistical analysis 
and machine learning for its simplicity and interpretability. Despite logistic regression being 
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a simple method, penalized logistic regression ranked second in discriminative performance 
after random forest (which is a much less interpretable classifier) in a recent empirical analysis 
of six classification algorithms for radiotherapy outcome prediction18. The presented model 
is unpenalized. Penalization might help the individual regression coefficients to converge as 
it alleviates the multicollinearity problem (Figure 2b) and will be explored in future studies.
With this study, we extend the list of distributed methods that are already implemented 
in the PHT: Bayesian networks19 and linear support vector machines4. Distributed learning 
approaches for other machine learning methods are available for future implementation, e.g., 
(convolutional) neural networks20.
An alternative to the PHT is DataSHIELD21, a mature open-source distributed data analysis 
and machine learning platform with multiple applications. It is based on the open-source 
software R and Opal data warehouses. The PHT infrastructure differentiates itself from 
DataSHIELD in multiple aspects:
• it is not limited to R but is compatible with multiple languages (e.g., Java, MATLAB, C#, 
Python, R);
• it offers analytical flexibility by not limiting the researcher to a fixed function library 
(DataSHIELD v4.0 comprises 140 R functions21);
• it uses Semantic Web technology to store and query data at sites but also allows relational 
databases and SQL queries;
• the long-term aim of the PHT infrastructure is to connect databases with routine clinical 
care data.
The presented PHT study only considers a very limited number of clinical data elements 
(T, N, M, overall stage, diagnosis year, survival follow-up). Arguably, individual predictions 
need many more data elements. Additional clinical (e.g., age, comorbidities), biological (e.g., 
genomics, proteomics), imaging (e.g., screening, radiomics22) and treatment sources (e.g., 
radiotherapy treatment planning) are likely to contain relevant data elements for the prediction 
of a survival outcome. Furthermore, the two-year survival outcome is not sufficient for clinical 
decision support, quality-of-life, toxicity and cost are also relevant for a balanced decision to 
be taken. However, due to the limited number of data elements required for inclusion, we 
could reach very high inclusion numbers and could show that the methodology of distributed 
learning scales to these numbers. Although the data quality is improving in routine care, the 
more data elements a study requires, the less complete datasets will be available. As quality 
improves, future studies are possible where additional data elements (not only prognostic but 
also predictive for treatment outcomes) can be included and thus better and more clinically 
relevant models can be developed using the proposed infrastructure.
This project shows distributed learning infrastructures are capable of delivering cohort 
sizes to rival those available to researchers from national registries. However, distributed 
approaches such as the PHT, where each institute must only satisfy its local information 
and research governance requirements, ease the bureaucratic burden of learning from 
internationally separated pools of patients, particularly between countries with differing 
information governance regimes. Furthermore, the system is much more flexible and makes 
including additional data elements into analyses a simple process. If an item is not present in 
a registry dataset, retrospectively adding this information to previous years is very difficult 
if not logistically impossible. Lastly, the infrastructure provides a mechanism to expedite the 
external validation of prognostic and predictive models in cohorts from different countries 
with different patient demographics, organizational cultures, and treatment regimens.
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Changes in the AJCC TNM cancer staging edition were not considered in this study nor 
was the more granular classification (e.g., T1a, T1b). The staging edition which was used 
by the physician is not often noted explicitly but future analyses may use the diagnosis year 
(or institutional information on when they ‘switched’ editions) as a predictor in the logistic 
regression model. Knowing the staging edition on a per patient level would make it possible 
to validate if more recent staging editions are indeed more prognostic and could generally 
improve the predictive performance of the trained models.
This study has shown that distributed machine learning using Semantic Web technology 
can be implemented in a short time frame to answer specific research questions. In future 
work, we will extend the CORAL community with more cancer centers and include more 
data elements noted in routine care. We expect therefore that, the PHT will enable researchers 
to rapidly train new prediction models as new patients and data elements become available: 
accelerating the speed at which clinical observations are turned into actionable knowledge.
The Personal Health Train infrastructure was deployed across eight healthcare institutes in 
five countries in four months. A two-year survival prediction model was trained and validated 
in more than 20 000 non-small cell lung cancer patients. This infrastructure demonstrably 
overcomes patient-privacy barriers to healthcare data sharing and implements distributed 
data analysis and machine learning across healthcare providers worldwide.
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Methods
Th is study was registered on clinicaltrials.gov8 (https://www.clinicaltrials.gov/ct2/show/
NCT03564457) on 11-06-2018 (fi rst posted date: 20-06-2018, actual study start date: 01-07-
2018). In all sites, the project was approved by their institutional review boards (IRBs) or 
was conform to national information and research governance regulations. Offi  cial project 
invitations were sent to eight sites on 18-06-2018 and two additional sites were contacted later 
but before the deadline of September 1. Figure 3 shows the project timeline.
F igure 3. Project timeline. ESTRO: European Society for Radiotherapy and Oncology.
Given that the PHT is a privacy-by-design infrastructure where no individual patient 
data leaves the individual healthcare provider, no researcher has access to the data, data is 
anonymized or pseudonymized, and given the number of patients involved, internal privacy 
offi  cers oft en felt informed consent was neither feasible nor necessary.
Patients
Exports of routine clinical care databases (sites A-B and D-H) or study cohorts (site C) 
identifi ed as non-small cell lung cancer patients were included in this study (Table 4). Data 
elements retrieved were the diagnosis, diagnosis date, T, N, and M stages, overall stage, date 
of last follow-up aft er the diagnosis date and vital status at last follow-up (alive or dead). If 
the diagnosis date was not available, date of fi rst treatment, date of histology or date of intake 
were allowed as a surrogate for the date of diagnosis. Various staging editions (AJCC TNM 
cancer staging editions 1-8) were published and implemented during the period of treatment.
Two-year survival was defi ned as a reported time interval between date of diagnosis and 
date of last follow-up of more than 2 * 365.24 days with a vital status ‘alive’ at last follow-up or 
a reported time interval between date of diagnosis and date of death of more than 2 * 365.24 
days. Two-year death was defi ned as date of death less than 730.48 days aft er the date of 
diagnosis. Two-year survival was labelled missing if date of diagnosis, date of last follow-up, 
or vital status at last follow-up were missing. Two-year survival was also defi ned as missing 
if the date of last follow-up was earlier than two years aft er the date of diagnosis and the vital 
status at last follow-up was ‘alive’ (right-censored).
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Table 4. Cohort information. NSCLC: non-small cell lung cancer. SBRT: stereotactic body radiotherapy. RT: 
radiotherapy. CHART: continuous, hyperfractionated, accelerated radiotherapy.
  Disease Interval Treatment
Site A
NSCLC Stage I-IV 
(histologically 
confirmed) 
January 
2008-August 
2016
(Chemo-)radiotherapy, surgery, chemotherapy. 
Filtered for having last follow-up records in 2018 or 
documented vital status.
Site B
NSCLC, Stage I-IV, 
histo-cytologically 
confirmed
October 
2004-May 
2018
(Chemo-)radiotherapy, chemotherapy, surgery, 
multimodality treatment.
Site C NSCLC, 1) Peripheral stage I, 2) stage III
1) 2005-2016, 
2) 2008-2013
1) SBRT only, 2) concurrent (chemo-)radiotherapy, 
surgery.
Site D
NSCLC Stage I-IV 
(either clinical diagnosis 
or histologically 
confirmed) 
2004-2017
Definitive radiotherapy (55Gy in 20 fractions, CHART, 
concurrent or sequential chemo-radiotherapy or other 
standard/accepted radical radiotherapy schedules) 
excluding SBRT or post-surgery adjuvant RT.
Site E
NSCLC, Stage I-IV 
(either clinical diagnosis 
or histologically 
confirmed)
1997-2018
First available T, N, and M staging information of lung 
cancer patients treated with curative and palliative 
RT. Includes post-surgery RT, (chemo-)radiotherapy, 
recurrences.
Site F NSCLC, Stage I-IV 1982-2018
First available T, N, M, and overall staging information of 
lung cancer patients treated with curative and palliative 
RT. Includes post-surgery RT, (chemo-)radiotherapy, 
recurrences.
Site G NSCLC, Stage I-IV 1955-2018
First available T, N, M, and overall staging information 
of lung cancer patients. Includes surgery, (chemo-)
radiotherapy.
Site H NSCLC, Stage I-IV 1971-2018
First available T, N, M, and overall staging information of 
all lung cancer patients treated with curative and palliative 
RT. Includes post-surgery RT, (chemo-)radiotherapy, 
recurrences, SBRT.
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FAIR data model
To make data FAIR, a data model has to be agreed upon between parties. As per prior 
work23 we have implemented this model using Semantic Web technology. In Figure S2, a 
graphical representation of the model is shown and on github24 (https://github.com/
RadiationOncologyOntology/20kChallenge/wiki/Data-model) the full data model 
including used classes and properties can be found.
FAIR data stations
Creating FAIR data out of clinical information systems generally involved the following tools
• Source systems: these are the clinical systems in which the data elements required for 
this study were stored
• ETL: software to extract data from source systems, transform data, and load it into a data 
warehouse
• Data warehouse: a database where data from multiple source systems are combined
• Mapping: transformation from the data warehouse schema to medical ontologies, e.g., 
the Radiation Oncology Ontology23 (ROO) or the National Cancer Institute thesaurus25 
(NCIt)
• Graph database: RDF database where data elements are FAIR.
Table 5 shows an overview of the tools used at the various care providers. To support the setup 
of mapping and graph database software, installation manuals were distributed and remote 
support was provided.
Table 5. Overview of tools used to make data FAIR. EMR: electronic medical records.
Provider Amsterdam (NL)
Cardiff
(WAL)
Maastricht 
(NL)
Manchester 
(ENG)
Nijmegen
(NL)
Rome
(IT)
Rotterdam
(NL)
Shanghai 
(CN)
Source 
systems
NKI-AVL 
Tumour 
registry
Canisc 
(Cancer 
Network 
Information 
System 
Cymru, 
NHS Wales 
Information 
Services)
HiX 
(Chipsoft, 
Netherlands), 
municipality 
population 
registry 
(survival 
data)
Clinical Web 
Portal (in 
house e-records 
system). Mosaiq 
radiotherapy 
oncology 
information 
system. Medway 
Sigma BI patient 
administration 
system.
Radiotherapieweb 
(in-house EMR), 
municipality 
population 
registry (survival 
data)
BOA26 
and 
Speed 
RO
OpenClinica, 
Microsoft 
Access
Chinese 
EMR
ETL tools MS SSIS MATLAB
SAP Business 
Objects, 
MATLAB
Pentaho data 
integration, SQL, 
Java, Python, R
PHP, SQL, 
MATLAB SQL MATLAB
In-house 
software
Data 
warehouse
MS SQL 
Server
MS SQL 
Server
SAP Business 
Objects PostgreSQL SQL Server
SQL 
Server None
Mapping D2RQ
Graph 
database Blazegraph
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Network for secure application distribution, execution, and communication
For the secure distribution of and messaging between applications, a solution called the 
Varian Learning Portal (VLP, Varian Medical Systems, Palo Alto, CA) was used. The VLP 
is a cloud-based system which has implemented user, site, and project management so that 
a research project consisting of multiple data providers and researchers can securely share 
applications and communication between applications. To connect the VLP to a local data 
station, a learning connector is installed at each data provider. The learning connector is a 
gateway through which applications and communication are handled. The iterative execution 
of applications and communication between them is called a learning run and each data 
provider can accept or deny each learning run. All communication and other actions are 
logged and auditable by members of a given project.
Applications for distributed cohort discovery, and learning
The VLP allows a certificate-based upload of applications. Each application group has two 
parts. One that runs at the VLP in the cloud (master application) and one at each of the sites 
(site application). Multiple application groups were developed in this project.
• The first application group’s aim is cohort discovery. An application is sent to each site 
to determine and communicate generic statistics (counts) of the available data in the 
FAIR data station. This cohort discovery application includes a SPARQL Protocol and 
RDF Query Language (SPARQL) query. Each site application reports its site statistics to 
a master application running at the VLP which are then reported back to the researcher 
who initiated the application. Multiple variations of this application group were employed 
to generate summary statistics for patient subgroups.
• The second application group aims to train a logistic regression (LR) model. Each LR 
site application can, given a SPARQL query, train a LR model from the local dataset. 
The regression coefficients of each site LR model and patient counts are then sent to the 
master application that reaches consensus in an iterative manner. Figure 4 illustrates the 
process followed in the LR application group.
• The third application group validates a given LR model on the sites. An application is 
sent to each site to compute model performance metrics (RMSE, ROC curve, AUC, 
calibration plots) and transfers these back to the master application which combines and 
passes them on to the researcher. Calibration plots reporting calibration-in-the-large and 
calibration slope are generated following Steyerberg27 and include Wilson confidence 
intervals implemented by Winkler and Nichols28.
The LR model is trained on patients treated between 1978 and 2012 and validated on all 
patients treated between 2012 and 2015. Only patients with complete diagnosis date, follow-
up date, follow-up status, and complete T, N, M, and overall stage after imputation are 
included. This approach simulates the development of an LR model and sequential validation 
on new data becoming available over time. This is a TRIPOD type 2b validation9.
The application used to train the LR coefficients in a distributed manner is based on the 
Alternating Direction Method of Multipliers (ADMM) and exemplary implementations by 
Boyd et al.(2011)29,30. ADMM decomposes the optimization problem underlying logistic 
regression (finding regression coefficients that maximize the log-likelihood of all training 
data) into an iterative optimization: each site computes regression coefficients that optimize 
a trade-off between maximizing the log-likelihood for the site’s local data and a degree 
of agreement with the network consensus (a combination of the regression coefficients 
determined at all sites). This trade-off includes a penalty for disagreeing with this consensus. 
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At the master, the sets of site-specific regression coefficients are combined to a new consensus 
and a new disagreement penalty value is determined. This consensus and the new penalty 
are then returned to each site to again optimize site-specific coefficients (the trade-off 
between maximizing log-likelihood and agreement with consensus changes because of the 
new consensus and disagreement penalty). This iterative procedure is repeated until the 
discrepancy between the sites’ local coefficients and the consensus, as well as the change in the 
consensus solutions over iterations is sufficiently small. For an excellent technical description 
of ADMM, we suggest Boyd et al. (2011)29. All application groups are implemented in 
MATLAB R2018a (Mathworks, Natick, MA). Code and accompanying documentation are 
available open-source31 (https://github.com/RadiationOncologyOntology/20kChallenge).
Data processing before LR training
The levels for each variable (T, N, M, and overall stage) are grouped in supercategories (Table 
6) to allow regression on data of different AJCC TNM cancer staging editions and to bundle 
similar categories.
Table 6. Supercategories for T, N, M, and overall stages grouping AJCC TNM cancer staging editions 1-8.
T N M Overall stage
0 T0 0 N0 0 M0 0 0
1 T1, T1a, T1b, T1c, T1mi, Tis 1 N1 1 M1, M1a, M1b, M1c I IA, IA1, IA2, IA3, IB
2 T2, T2a, T2b 2 N2 X MX II IIA, IIB
3 T3 3 N3 III III, IIIA, IIIB, IIIC
4 T4 X NX IV IV, IVA, IVB
X TX Occult Occult
T, N, M, and overall stages were dummy-coded to estimate the individual effect of each stage 
on two-year survival. T1, N0, M0 and overall stage I categories were used as the reference 
categories to avoid multicollinearity issues in the regression model. For example, the ordinal 
variable T stage, which takes six values (0 to 4, X), is converted to five binary variables 
representing T0, T2, T3, T4, TX.
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Imputation
If a patient misses entries for one or more of the variables T, N, M, and/or overall staging (but 
not all of them), imputation of the missing values is attempted. A detailed imputation process 
description is presented in Figure S3 (Supplementary Information) and an outline is given 
below.
First, the missing values are logically induced from the permitted combinations of T, N, M, 
and overall stages. For example, a patient diagnosed in 2011 with N0M0 and overall stage IIA 
but missing T can only have T2b according to TNM edition 7.
If the logical imputation is ambiguous because multiple imputation results are possible, 
the missing values are imputed probabilistically based on a subset of patients treated at the 
same site. This subset contains patients treated at the same site, within the time interval 
corresponding to the selected AJCC TNM edition, and matching the available variables of 
the patient. This subset also contains patients for which missing values are logically imputed 
so that probabilistic imputation is also feasible for sites E and H which miss some variable 
for all patients. The empirical probability of each T, N, M, and overall stage combination 
observed in this patient subset is computed and one of these combinations is randomly 
sampled according to the computed empirical probabilities. For example, a patient diagnosed 
in 2013 with T1aN0 and overall stage IV but missing M can be imputed with M1a or M1b 
according to TNM edition 7. If there are 30 patients with T1aN0M1a & overall stage IV and 
70 patients with T1aN0M1b & overall stage IV diagnosed starting 2010 and before 2018, the 
missing M value is imputed by 1a with probability 0.3 and by 1b with probability 0.7. This 
probabilistic imputation procedure assumes variables to be missing at random which is a 
simplifying assumption in routine clinical care data.
This imputation procedure is repeated for all available TNM editions (1-8). To decide on a 
single imputation for a given patient, the most recent TNM edition meeting two criteria is 
selected:
• it was effective before or in the patient’s year of diagnosis;
• it yields a complete imputation.
The modeling choice to also use preceding editions takes into account the possibility that the 
treating physician has not yet adopted the newest AJCC TNM cancer staging edition.
The following official effective dates for AJCC TNM cancer staging editions are used32:
• Edition 1: 1978 – 1983
• Edition 2: 1984 – 1988
• Edition 3: 1989 – 1992
• Edition 4: 1993 – 1997
• Edition 5: 1998 – 2002
• Edition 6: 2003 – 2009
• Edition 7: 2010 – 2017
• Edition 8: 2018 – present
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F igure 4. A simplifi ed process description of the distributed logistic regression application group. VLP: Varian 
Learning Portal. ADMM: Alternating Direction Method of Multipliers.
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Figure S1. Calibration plots of the validation data for all sites excluding site G (Figure 2d). AUC: area under the 
receiver operating characteristic curve.
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(f)
(g)
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Tab le S1. Patient counts with stages IA, IB, IIA, IIB, IIIA, IIIB, IV in the validation cohort and corresponding model 
performance per site for the presented model and the AJCC TNM cancer staging edition 7 survival probabilities10. 
Survival probabilities for stage 0 and Occult are not available in the reference. Th e corresponding patients were thus 
excluded. Patients not staged according to edition 7 in the validation cohort were also excluded. AUC: area under the 
receiver operating characteristic curve. CI: confi dence interval.
Site
Validation cohort patient 
counts
(stage IA, IB, IIA, IIB, IIIA, IIIB, IV)
Model performance
Logistic regression AJCC edition 7
AUC 95%-CI AUC 95%-CI Δ AUC
Site A 2803 0.87 [0.84, 0.89] 0.86 [0.84, 0.89] 0.00
Site B 87 0.67 [0.54, 0.78] 0.69 [0.56, 0.80] -0.02
Site C 131 0.54 [0.43, 0.64] 0.52 [0.42, 0.61] 0.02
Site D 273 0.59 [0.52, 0.66] 0.59 [0.53, 0.65] 0.00
Site E 2455 0.73 [0.70, 0.74] 0.71 [0.69, 0.73] 0.01
Site F 939 0.73 [0.69, 0.76] 0.72 [0.68, 0.75] 0.01
Site G 878 0.71 [0.67, 0.75] 0.71 [0.66, 0.74] 0.01
Site H 341 0.76 [0.69, 0.82] 0.77 [0.69, 0.81] -0.01
Total 7907
F igure S2. A graphical representation of the data model employed in the distributed learning network.
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F igure S3. Imputation process. Th e TNM imputation wrapper function (a) is the outermost function which uses 
the TNM imputation function (b) and the Filter cell by row function (c) as subfunctions. Th e wrapper function 
has two input groups: data for the patients that are to be imputed and data for patients that act as the reference for 
probabilistic imputation. For both input groups, T, N, M, overall stage, and diagnosis year per patient are needed. 
TNM: cancer staging system based on tumor size (T), lymph node involvement (N) and metastasis (M). TNM 
edition: one of eight released TNM cancer staging system editions eff ective since 1978 and in non-overlapping time 
periods. TNMS: combination of TNM and cancer stage (S) for a patient (can contain missing values) or in the 
TNMS library (complete cases). Years: year of diagnosis corresponding with time of TNM staging, and used to 
determine the currently eff ective TNM edition. TNMS ref: reference patient TNMS combinations to be used for 
logic probabilistic imputation. TNMS library: library of valid combinations of TNM and cancer stages according 
to a specifi c TNM edition. Logic imputation: imputation of a missing TNMS value according to a single conclusive 
combination in the TNMS library. Logic probabilistic imputation: imputation of a missing TNMS value according 
to multiple inconclusive combinations in the TNMS library and their respective probabilities of occurrence in the 
TNMS reference cell. Imputation code: patient specifi c codes to indicate if the TNMS entries follow the TNM edition 
logic and the type of imputation performed (if any).
(c)
Centralized learning
Adapted from Deist, Timo M., et al. "Machine learning algorithms for outcome 
prediction in (chemo) radiotherapy: An empirical comparison of classifi ers." 
Medical physics (2018).
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Chapter 4
Machine learning algorithms for outcome 
prediction in (chemo)radiotherapy: an 
empirical comparison of classifi ers
Abstract
Purpose
Machine learning classification algorithms (classifiers) for prediction of treatment response 
are becoming more popular in radiotherapy literature. General machine learning literature 
provides evidence in favor of some classifier families (random forest, support vector machine, 
gradient boosting) in terms of classification performance. The purpose of this study is to 
compare such classifiers specifically for (chemo)radiotherapy datasets and to estimate their 
average discriminative performance for radiation treatment outcome prediction.
Methods
We collected 12 datasets (3484 patients) from prior studies on post-(chemo)radiotherapy 
toxicity, survival, or tumor control with clinical, dosimetric, or blood biomarker features from 
multiple institutions and for different tumor sites, i.e. (non-)small cell lung cancer, head and 
neck cancer, and meningioma. Six common classification algorithms with built-in feature 
selection (decision tree, random forest, neural network, support vector machine, elastic net 
logistic regression, LogitBoost) were applied on each dataset using the popular open-source 
R package caret. The R code and documentation for the analysis are available online1. All 
classifiers were run on each dataset in a 100-repeated nested 5-fold cross-validation with 
hyperparameter tuning. Performance metrics (AUC, calibration slope and intercept, accuracy, 
Cohen’s kappa, and Brier score) were computed. We ranked classifiers by AUC to determine 
which classifier is likely to also perform well in future studies. We simulated the benefit for 
potential investigators to select a certain classifier for a new dataset based on our study (pre-
selection based on other datasets) or estimating the best classifier for a dataset (set-specific 
selection based on information from the new dataset) compared to uninformed classifier 
selection (random selection).
Results 
Random forest (best in 6/12 datasets) and elastic net logistic regression (best in 4/12 datasets) 
showed the overall best discrimination but there was no single best classifier across datasets. 
Both classifiers had a median AUC rank of 2. Pre-selection and set-specific selection yielded a 
significant average AUC improvement of 0.02 and 0.02 over random selection with an average 
AUC rank improvement of 0.52 and 0.65, respectively.
Conclusion 
Random forest and elastic net logistic regression yield higher discriminative performance in 
(chemo)radiotherapy outcome and toxicity prediction than other studied classifiers. Thus, one 
of these two classifiers should be the first choice for investigators when building classification 
models or to benchmark one’s own modelling results against. Our results also show that an 
informed pre-selection of classifiers based on existing datasets can improve discrimination 
over random selection.
AN EMPIRICAL COMPARISON OF CLASSIFIERS 65
4
Introduction
Machine learning algorithms for predicting (chemo)radiotherapy outcomes (e.g., survival, 
treatment failure, toxicity) are receiving much attention in literature, for example in 
decision support systems for precision medicine2,3. Currently, there is no consensus on an 
optimal classification algorithm. Investigators select algorithms for various reasons: the 
investigator’s experience, usage in literature, data characteristics and quality, hypothesized 
feature dependencies, availability of simple implementations, and model interpretability. 
One objective criterion for selecting a classifier is to maximize a chosen performance metric, 
e.g., discrimination (expressed by the area under the receiver operating characteristic curve, 
AUC). Here, we discuss the performance of binary classifiers in (chemo)radiotherapy 
outcome prediction, i.e. algorithms that predict whether or not a patient has a certain 
outcome. We empirically study the behaviour of existing simple implementations of 
classifiers on a range of (chemo)radiotherapy outcome datasets to possibly identify a 
classifier with overall maximal discriminative performance. This is a relevant question 
for investigators who search for a rational basis to support their choice of a classifier 
or who would like to compare their own modelling results to established algorithms. 
We employ various open-source R packages interfaced with the R package caret4 (version 6.0-
73) that is readily available for investigators and has shown to produce competitive results5. 
With our results, we also wish to provide guidance in the current trend to delegate modelling 
decisions to machine learning algorithms.
Large scale studies in the general machine learning literature5–7 provide evidence in favor of 
some classifier families (random forest (rf), support vector machine (svm), gradient boosting 
machine (gbm)) in terms of classification performance. In our study, we investigate how 
these results translate to (chemo)radiotherapy datasets for treatment outcome prediction/
prognosis. To the best of our knowledge, this is the first study to investigate classifier 
performance on a wide range of such datasets. The studied features are clinical, dosimetric, 
and blood biomarkers.
Within the framework of existing classifier implementations, we attempt to answer three 
research questions:
• Is there a superior classifier for predictive modelling in (chemo)radiotherapy?
• How dataset-dependent is the choice of a classifier?
• Is there a benefit of choosing a classifier based on empirical evidence from similar 
datasets (pre-selection)? 
Parmar et al. (2015)8 compared multiple classifiers and feature selection methods (i.e. filter-
based feature selection) on radiomics data using the caret package. We build upon this work 
and extend the analysis to 12 datasets outside the radiomics domain. We omit filter methods 
because all classifiers in our study comprise built-in feature selection methods (i.e. embedded 
feature selection) and the main advantage of filter methods, i.e. low computational cost per 
feature, is not relevant for our datasets with only modest numbers of features.
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Material and Methods
Data collection
Twelve datasets (3484 patients) with treatment outcomes described in previous studies were 
collected from public repositories (www.cancerdata.org) or provided by collaborators. Table 
1 characterizes these datasets. Given availability, some datasets consist of subsamples of or 
contain fewer/more patients and/or features than the cohorts described in the original studies. 
Two datasets were excluded after a preliminary analysis (these datasets are also not mentioned 
in table 1) where none of the studied classifiers resulted in an average AUC above 0.51, which 
is evidence that they contain no discriminative power. Datasets without discriminative 
power are not suitable for this analysis as we would be unable to determine differences in 
discriminative performance across classifiers. The patient cohorts of 2 datasets, Wijsman et al. 
(2015 and 2017), partially overlap but each dataset lists a different outcome (esophagitis and 
pneumonitis). Datasets were anonymized in the analysis because their identity is not relevant 
for interpreting the results and to encourage investigators to share their datasets.
Non-binary outcomes were dichotomized, e.g., overall survival was translated into 2-year 
overall survival in the dataset of Carvalho et al. (2016). Missing data was imputed for training 
and test sets (the splitting of datasets into training and test sets is described in section 
Experimental Design) by medians for continuous features and modes for categorical features 
based on the training set. Basing the imputation on the training set avoids information 
leakage from test to training sets. Categorical features in training and test sets were dummy 
coded, i.e. representing categorical features as a combination of binary features, based on 
the combined set for classifiers that cannot handle categorical features (see table 2). Dummy 
coding on the combined set ensures that the coding represents all values observed in a 
dataset. Features with zero variance in training sets were deleted in the training set and in 
the corresponding test set. Additionally, we removed near-zero variance features for glmnet 
to avoid the classifier implementation from crashing during the fitting process. Features in 
training sets were rescaled to the interval [0,1] and the same transformation was applied to the 
corresponding test sets. Rescaling is needed for certain classifiers, e.g., svmRadial. All these 
operations (imputation, dummy coding, deleting (near-)zero variance features, rescaling) 
were performed independently for each pair of training and test sets (step 2 in figure 1).
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Table 1. D
ataset characteristics. Th
e num
ber of features is determ
ined before pre-processing.
D
ataset
D
isease
O
utcom
e
Prevalence (in %
)
Patients
Features
Feature types
Source
Belderbos et al. 
(2005) 9
N
on-sm
all cell lung cancer
G
rade ≥2 acute 
esophagitis
27
156
22
Clinical, dosim
etric, blood
Private
Bots et al. (2017) 10
H
ead and neck cancer
2-year overall survival
42
137
10
Clinical, dosim
etric
Private
Carvalho et al. 
(2016) 11
N
on-sm
all cell lung cancer
2-year overall survival
40
363
18
Clinical, dosim
etric, blood
Public
12
Janssens et al. (2012) 13
Laryngeal cancer
5-year regional control
89
179
48
Clinical, dosim
etric, blood
Private
Jochem
s et al. (2016) 14
N
on-sm
all cell lung cancer
2-year overall survival
36
327
9
Clinical, dosim
etric
Private
Kw
int et al. (2012) 15
N
on-sm
all cell lung cancer
G
rade ≥2 acute 
esophagitis
61
139
83
Clinical, dosim
etric, blood
Private
Lustberg et al. 
(2016) 16,17
Laryngeal cancer
2-year overall survival
83
922
7
Clinical, dosim
etric, blood
Private
M
orin et al. 
(forthcom
ing)
M
eningiom
a
Local failure
36
257
18
Clinical
Private
O
berije et al. (2015) 18
N
on-sm
all cell lung cancer
2-year overall survival
36
536
20
Clinical, dosim
etric
Public
19
O
lling et al. (2017) 20 
Sm
all and non-sm
all cell lung 
cancer 
O
dynophagia 
prescription m
edication
67
131
47
Clinical, dosim
etric
Private
W
ijsm
an et al. 
(2015) 21
N
on-sm
all cell lung cancer
G
rade ≥2 acute 
esophagitis
36
149
11
Clinical, dosim
etric, blood
Private
W
ijsm
an et al. 
(2017) 22
N
on-sm
all cell lung cancer
G
rade ≥3 radiation 
pneum
onitis
14
188
18
Clinical, dosim
etric, blood
Private
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Classifiers
Six common classifiers were selected and their implementations were used via their interfacing 
with the open-source R package caret. The selection includes classifiers frequently used in 
medical data analysis and advanced classifiers such as random forests or neural networks.
• Elastic net logistic regression is a regularized form of logistic regression, which models 
additive linear effects. The added shrinkage regularization (i.e. feature selection) makes 
it is suitable for datasets with many features while maintaining the interpretability of a 
standard logistic regression.
• Random forests generate a large number of decision trees based on random subsamples 
of the training set while also randomly varying the features used in the trees. Random 
forests allow modelling non-linear effects. A random forest model is an ensemble of 
many decision tree models and is therefore difficult to interpret.
• Single-hidden-layer neural networks are simple versions of multi-layer perceptron neural 
network models, which are currently popularized by deep neural network applications 
in machine learning. In the hidden layer, auxiliary features are generated from the input 
features which are then used for classification. The weights used to generate auxiliary 
features are derived from the training set. The high number of weights require more 
training data than other simpler algorithms and reduce interpretability. However, if 
sufficient data is available, complex relationships between features can be modelled.
• Support vector machines with a radial basis function (RBF) kernel transform the original 
feature space to attain a better separation between classes. This transformation, however, 
is less intuitive than linear SVMs where a separating hyperplane is in the original feature 
space.
• LogitBoost (if used with decision stumps as in this paper) learns a linear combination 
of multiple single feature classifiers. Training samples that are misclassified in early 
iterations of the algorithm are given a higher weight when determining further classifiers. 
The final model is a weighted sum of single feature classifiers. Similar to random forests, 
it builds an ensemble of models which is difficult to interpret.
• A decision tree iteratively subdivides the training set by selecting feature cutoffs. Decision 
trees can model non-linear effects and are easily interpretable as long as the tree depth 
is low.
Classifier details can be found in general machine learning textbooks23,24. Table 2 further 
characterizes these classifiers. We use the option in caret to return class probabilities for all 
classifiers, including non-probabilistic classifiers like svmRadial. Classifier hyperparameters, 
i.e. model-intrinsic parameters that need to be adjusted to the studied data prior to modelling, 
were tuned for each classifier using a random search: 25 randomly chosen points in the 
hyperparameter space are evaluated and the point with the best performance metric (we 
chose the AUC in this study) is selected. The boundaries of the hyperparameter space are 
given in caret.
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Table 2. Classifier characteristics.
Classifier caret4 label  R package Requires dummy coding
Tuned hyper-
parameters
Elastic net logistic 
regression glmnet glmnet
25 Yes α, λ
Random forest rf randomForest26 No mtry
Single-hidden-layer neural 
network nnet nnet
27 No size, decay 
Support vector machine 
with radial basis function 
(RBF) kernel
svmRadial kernlab28 Yes σ, С
LogitBoost LogitBoost caTools29 Yes nlter
Decision tree rpart rpart30 No cp
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Experimental Design
For each classifier, test set (or out-of-sample) performance metrics (AUC, Brier score, accuracy, 
and Cohen’s kappa) were estimated for each of the 12 datasets. The performance metric 
estimator was the average performance metric computed from the outer test folds in a nested 
and stratified 5-fold cross-validation (CV). The experiment was repeated 100 times. The 100 
times repeated nested cross-validation yields a better estimate of the true test set performance 
by randomly simulating many scenarios with varying training and test set compositions.
Figure 1. Experimental design: each dataset is split into 5 stratified outer folds (step 1). For each of the folds, the data is 
pre-processed (imputation, dummy coding, deleting zero variance features, rescaling) (step 2). The hyperparameters 
are tuned in the training set via a 5-fold inner CV (steps 3-5). Based on the selected hyperparameters, a model is 
learned on the training set (step 6) and applied on the test set (step 7). Performance metrics are calculated on the test 
set (step 8) and stored for all outer folds. This process is repeated 100 times for each classifier. Randomization seeds 
are stable across classifiers within a repetition to allow pairwise comparison.
The experimental design is depicted in figure 1: Each dataset was split into 5 random 
subsamples stratified for outcome classes (step 1 in figure 1), each of them acting once as a 
test set and 4 times as a part of a training set. The number of inner and outer folds was set to 
5 following standard practice24(p242). Data pre-processing is done per pair of training and test 
sets (step 2; see details in section Datasets). The models were trained on the training set (step 
6) and applied on the test set (step 7) to compute the performance metrics for the test set (step 
8) resulting in 5 estimates per performance metric (i.e. 1 per outer fold). During the training 
in each outer fold, the best tuning parameters were selected from the random search (see 
section Classifiers) according to the maximum AUC of an inner 5-fold CV. In the inner CV, 
the training set was again split into 5 subsamples and models with different tuning parameters 
were compared (steps 3-5). The nested 5-fold CV was repeated 100 times with different 
randomization seeds which are used, e.g., for generating the outer folds in step 1. Note that the 
performance metrics computed on the outer test folds of any two classifiers can be analysed 
by pairwise comparison because the classifiers were trained (step 6) and tested (step 7) on the 
same training and test sets for a specific dataset within each of the 100 repetitions. 
The mean AUC, Brier score, accuracy, and Cohen’s kappa were computed from the 5 
estimates of the 5 folds in the outer CV. Calibration intercept and slope were computed from 
a linear regression of outcomes and predicted outcome probabilities for each of the 5 outer 
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folds. To attain aggregated calibration metrics over the 5 outer folds of the CV, the mean 
absolute differences from 0 and 1 were computed for the calibration intercept and slope, 
respectively. Classifier rankings were computed per dataset and repetition by ordering the 
classifiers’ CV-mean AUC (i.e. the average AUC for 5 test sets) in descending order and then 
assigning the ranks from 1 to 6. Using CV-mean AUCs and CV-mean AUC ranks, we answer 
research questions 1 & 2. We chose AUC for the analysis following Steyerberg et al. (2010)31. 
They emphasize the importance of discrimination and calibration metrics when assessing 
prediction models. For the simplicity, we restricted the extended analysis to discrimination 
(AUC) but also report results for calibration and other metrics in appendix A. 
To address the question of pre-selection (research question 3), we assess the advantage of 
choosing a classifier based on performance metrics from similar datasets, which we call pre-
selection below. To estimate the benefit of our classifier pre-selection for a new dataset and 
to compare it to alternative strategies, the results of the experiment above were used as input 
for a simulation. For each outer fold of the 1200 5-fold CVs (12 datasets * 100 repetitions * 5 
folds = 6000 folds), 3 classifier selections were made and tested on the test set that belongs to 
the specific outer fold:
• pre-selecting the classifier according to the average AUC rank in all other datasets 
(excluding all folds from the current dataset),
• selecting the classifier that performed best in the inner CV on the training set,
• randomly selecting a classifier.
Pre-selecting the classifier for one dataset that had the best average AUC rank in the 
other datasets simulates the scenario in which an investigator bases their classifier choice 
on empirical evidence as is reported in this manuscript. Randomly selecting a classifier 
represents the case where an investigator chooses a classifier without any prior knowledge 
about the dataset that (s)he is about to analyze. Selecting the tuned classifier with best inner 
CV performance corresponds to evaluating multiple classifiers on the training dataset and thus 
including dataset-specific information in the classifier selection. The performance metrics are 
averaged over all 500 outer folds (5 folds * 100 repetitions) for each of the 12 datasets.
The documented R code used for the analysis is available online1.
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Results
Running 1 nested 5-fold cross-validation and computing the metrics on 1 dataset for all 6 
classifiers allows 1 comparison of classifiers. This was applied on 12 different datasets, with 
each run repeated 100 times for a total of 1200 comparisons. The total computation time was 
approximately 6 days on an Intel Core i5-6200U CPU (or 15 seconds per classifier per dataset 
per outer fold, on average).
The results are presented and discussed threefold:
1. results aggregated over all datasets and repetitions to determine the presence of a 
superior classifier,
2. separate results for each dataset but aggregated over repetitions to determine dataset 
dependency,
3. a simulation of classifier selection methods in new datasets to estimate the relative effect 
of classifier pre-selection.
The detailed analysis is restricted to the classifiers’ discriminative performance according to 
the AUC. Results for the remaining metrics (Brier score, calibration intercept/slope, accuracy, 
and Cohen’s kappa) are reported in appendix A.
Results aggregated over all datasets
Figure 2 shows the distribution of classifier rankings based on the average AUC (12 datasets 
* 100 repetitions = 1200 data points per classifier). Figure 3 depicts pairwise comparisons for 
each classifier pair (1200 comparisons per pair). The numbers in the plot indicate how often 
classifier A (y-axis) achieved an AUC greater than classifier B (x-axis). Coloring indicates 
whether the increased AUCs of classifier A are statistically significant (violet) or not (light 
violet). Untested pairs are colored grey. The significance cutoff was set to the 0.05-level (one-
sided Wilcoxon signed-rank test, Holm-Bonferroni correction for 15 tests).
rf and glmnet showed the best median AUC rank, followed by nnet, svmRadial, LogitBoost, 
and rpart (figure 2). At the low end of the ranking, rpart showed poor discriminative 
performance. Manual inspection of the rpart models showed that rpart frequently returns 
empty decision trees for particular sets (for 34%, 67%, 35%, 58% of all outer folds for sets D, 
F, K, L, respectively). In pairwise comparisons, rf and glmnet significantly outperformed all 
other classifiers (figure 3). rf exhibited a small but statistically insignificant better AUC rank 
than glmnet. 
The results in figures 2 and 3 indicate the existence of a significant classifier ranking for 
these datasets. However, the considerable spread per classifier in figure 2 and the low pairwise 
comparison percentages (between 57% and 88% in figure 3) also suggest a yet unobserved 
dependency for classifier performance. To this end, the relationship between datasets and 
varying classifier performance is investigated.
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Figure 2. Box- and scatterplot of the AUC rank (lower being better) per outer 5-fold CV aggregated over all datasets 
and repetitions (12 datasets * 100 repetitions = 1200 data points per classifier).
Figure 3. Pairwise comparisons of each classifier pair (12 datasets * 100 repetitions = 1200 comparisons per pair). 
The numbers in the plot indicate how often classifier A (y-axis) achieved an AUC greater than classifier B (x-axis). 
The color indicates whether the increased AUCs by classifier A are statistically significant (violet), insignificant (light 
violet), or have not been tested (grey). The significance cutoff was set to the 0.05-level (one-sided Wilcoxon signed-
rank test, Holm-Bonferroni correction for 15 tests).
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Results separate for each dataset
Figure 4 shows the average AUC for each pair of classifier and dataset (100 repetitions = 100 
data points per pair). Figure 5 depicts the average rank derived from the AUC (100 data points 
per pair).
rf and glmnet generally yielded higher AUC values and AUC ranks per dataset (figures 4 & 
5). However, this observation is not consistent over all datasets: e.g., nnet outperforms rf in 
sets G, J, and K, and svmRadial outperformed glmnet in sets A and C.
The results in the figures 4 and 5 indicate that dataset-specific properties impact the 
discriminative performance of classifiers. These results challenge our proposition that one can 
pre-select classifiers for predictive modelling in (chemo)radiotherapy based on representative 
datasets from the same field.
Figure 4. The mean AUC for each pair of classifier and dataset (100 repetitions = 100 data points per pair).
Figure 5. The mean rank derived from the AUC (100 repetitions = 100 data points per pair).
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Effects of empirical classifier pre-selection on discriminative performance
Table 3 lists, for each dataset, the name and average AUCs, i.e. averaged over all 100 repetitions, 
for random classifier selection, classifier pre-selection, and set-specific classifier selection.
The pre-selection procedure always results in rf or glmnet. The mean benefit of empirically 
pre-selecting a classifier is small: the AUC improvement ranges between -0.01 and 0.07 with 
a mean of 0.02. In a pairwise comparison over all datasets (p < 0.05, one-sided Wilcoxon 
signed-rank test), the AUC values by pre-selection were significantly larger than the AUC 
values by random selection. The AUC rank improves by 0.52 on average. Including dataset-
specific information by inner CV yields a mean AUC improvement of 0.02 and improves 
the rank, on average, by 0.65. In a pairwise comparison of set-specific and random classifier 
selection over all datasets (p < 0.05, one-sided Wilcoxon signed-rank test), the AUC increase 
was also statistically significant.
Given this simulation, the expected benefit of pre-selecting a classifier for a new dataset 
based on results from (chemo)radiotherapy-specific numerical studies is limited with an 
average increase in AUC of 0.02.
Table 3. For each dataset, the AUC rank averaged over all repetitions when (a) randomly selecting a classifier 
(Random classifier), (b) pre-selecting the classifier with the average best AUC rank in all other datasets, i.e. without 
any information about the current dataset (Pre-selected classifier), (c) selecting the classifier that yielded the highest 
AUC in the inner CV (Set-specific classifier). Improvements in average AUC and average AUC rank compared to (a) 
are reported. The average AUC improvements by pre-selection and set-specific selection were tested for statistical 
significance (p < 0.05, one-sided Wilcoxon signed-rank test) and found to be statistically significant (*). No other 
statistical tests besides the two aforementioned tests were conducted.
Random 
classifier Pre-selected classifier Set-specific classifier
Rank
Name
Rank AUC Rank AUC
Dataset
Mean Mean Increase Increase Mean Increase Increase
Set A 3.43 glmnet 3.64 -0.21 0.00 3.10 0.33 0.02
Set B 3.44 rf 2.92 0.52 0.02 3.31 0.13 0.00
Set C 3.49 rf 1.94 1.55 0.05 2.78 0.71 0.03
Set D 3.59 rf 2.60 0.99 0.05 3.31 0.28 0.02
Set E 3.53 rf 1.89 1.63 0.05 2.58 0.94 0.03
Set F 3.57 rf 2.99 0.58 0.04 3.52 0.05 0.01
Set G 3.43 rf 3.81 -0.39 0.00 1.70 1.73 0.05
Set H 3.65 rf 1.59 2.06 0.07 1.71 1.93 0.06
Set I 3.49 glmnet 3.50 0.00 0.00 2.08 1.42 0.03
Set J 3.52 rf 4.18 -0.67 -0.01 3.41 0.11 0.01
Set K 3.59 rf 3.33 0.26 0.02 3.20 0.39 0.02
Set L 3.44 rf 3.50 -0.06 0.00 3.66 -0.22 -0.01
Mean 3.51   2.99 0.52 0.02* 2.86 0.65 0.02*
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Discussion
Our results suggest that there is indeed an overall ranking of classifiers in (chemo)radiotherapy 
datasets, with rf and glmnet leading the ranking. However, we also observe that the performance 
of a classifier depends on the specific dataset. Pre-selecting classifiers based on evidence from 
related datasets would, on average, provide a benefit for investigators because it increases 
discriminative performance. An increase in average discriminative performance is desirable 
in that an investigator would be less likely to discard their data because of a perceived absence 
of predictive or prognostic value. The estimated 0.02 mean AUC improvement might appear 
small but it comes ‘for free’ with classifier selection based on empirical evidence from multiple 
radiotherapy datasets. Furthermore, the 0.02 AUC improvement is relative to random classifier 
selection. If an investigator had initially chosen rpart, which is the overall worst performing 
classifier in our study, switching to the preselected classifier would result in an average AUC 
increase of 0.07. Switching from LogitBoost, which is the second worst performing classifier 
in our study, to the preselected classifier would result in an average AUC increase of 0.04. 
The results in table 3 show that classifier pre-selection and set-specific classifier selection, on 
average, yield the same AUC increase. We think that the usefulness of set-specific classifier 
selection is dependent on the size of the training set: classifier pre-selection is preferable 
for small datasets, set-specific classifier selection is better for larger datasets. Classifier pre-
selection represents choosing classifiers using evidence from a large collection of similar 
datasets from the general radiotherapy outcome domain. Set-specific classifier selection 
represents choosing classifiers based on the training set, which is a considerably smaller 
evidence base but comes from the patient group under investigation. If the training dataset 
is too small, selecting classifiers based on results from other datasets might be less-error 
prone. On the contrary, if an investigator has collected a large dataset, they have the option to 
conduct set-specific classifier selection (with all 6 classifiers) for their training data using our 
documented R code1.
In table 3, one can observe that the pre-selected classifier is mostly rf and sometimes glmnet. 
To understand this behaviour, consider dataset A: glmnet was pre-selected for set A by selecting 
the classifier with the best average AUC rank in all other sets (excluding set A). Note that, for 
all 12 datasets together, the average AUC rank for rf is only slightly better than for glmnet 
(2.29 for rf and 2.45 for glmnet; the average of the rows in figure 5). Since glmnet performs 
badly while rf performs best in set A, excluding this information leads to a better average 
AUC rank for glmnet and a worse average AUC rank for rf in the remaining 11 datasets. As a 
consequence, glmnet becomes the pre-selected classifier for this dataset. A similar behaviour 
is observed for set I but not in sets C, D, E, H, where glmnet also performs worse than rf but the 
difference between both classifiers is smaller and does not induce a switch in the pre-selected 
classifier.
The result that classifier pre-selection is as good as set-specific selection in the studied 
datasets does not imply that one cannot determine a better classifier for a new dataset. Our 
implementation of set-specific classifier selection only evaluates the performance of various 
classifiers but does not directly take into account properties of the dataset itself. For example, 
if an investigator collected a dataset in which the outcome has a quadratic dependency 
on a feature, glmnet would not be able to capture this relation (since it models only linear 
effects) but rf would. However, pre-selecting a classifier based on results from other (chemo)
radiotherapy datasets works well on average. Furthermore, including set-specific classifier 
selection complicates the modelling process and therefore might not be desirable.
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In this study, we collected 12 datasets for different treatment sites, i.e. (non-) small cell 
lung cancer, head and neck cancer, meningioma with different outcomes, i.e. survival, 
pneumonitis, esophagitis, odynophagia, regional control. However, this collection is 
certainly not a complete representation of treatment outcome datasets analyzed in the field of 
radiotherapy. Furthermore, we only studied one implementation of classifiers while classifier 
performance may vary between implementations. Past studies, however, indicate that 
classifier implementations in R interfaced with caret are competitive5. Given the apparent lack 
of comparative classifier studies in radiotherapy, our intention has been to provide numerical 
evidence for classifier selection to investigators even though our analysis is not exhaustive.
We intentionally limited the analysis to classifier selection while ignoring factors such as the 
investigator’s experience, usage in literature, hypothetical feature dependencies, and model 
interpretability. This restriction imitates the current trend to delegate modelling decisions 
to machine learning algorithms and/or non-domain experts. Nonetheless, we feel the need 
to emphasize that including these factors has merit. Furthermore, expertise on a specific 
classifier could warrant its selection: Lavesson and Davidsson (2006)32 observed in a study 
on 8 datasets from different research domains that the impact of hyperparameter tuning 
exceeds that of classifier selection. Therefore, the investigator could tune a classifier for better 
performance by also tuning the hyperparameters outside the subset of hyperparameters 
tuneable inside caret. Even in those cases, however, we suggest comparing these results 
to simpler implementations of rf and glmnet as these classifiers on average have the best 
discriminative performance according to this study. Finally, for the clinical implementation 
of classifiers, model interpretability is arguably a major requirement33: this view is also 
convincingly motivated by Caruana et al.34. Fortunately, our study shows that glmnet, which is 
an intuitive classifier, is also one of the best performing classifiers.
Conclusion
We have modelled treatment outcomes in 12 datasets using 6 different classifier 
implementations in the popular open-source software R interfaced with the package caret. 
Our results provide evidence that the easily interpretable elastic net logistic regression and 
the complex random forest classifiers generally yield higher discriminative performance in 
(chemo)radiotherapy outcome and toxicity prediction than the other classifiers. Thus, one of 
these two classifiers should be the first choice for investigators to build classification models or 
to compare one’s own modelling results. Our results also show that an informed pre-selection 
of classifiers based on existing datasets improves discrimination over random selection.
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Appendix A
Table A1 lists performance metrics per classifier. These values are averaged over all repetitions 
and datasets (100 repetitions * 12 datasets = 1200 data points each). Accuracy and Cohen’s 
kappa were computed at the 0.5-cutoff. Calibration fails in some outer folds for every classifier 
resulting in either large or undefined values for intercept and/or slope. This failure occurs 
frequently with nnet and rpart. Undefined (NaN) values are excluded when calculating the 
median.
Table A1. Median performance metrics per classifier aggregated over repetitions and datasets (1200 data points 
each). Undefined (NaN) values are excluded when calculating the median.
Classifier AUC Brier score Accuracy Cohen’s kappa
Calibration 
intercept 
error
Calibration 
slope error
rf 0.71 0.19 0.70 0.14 0.12 0.38
glmnet 0.71 0.20 0.70 0.14 0.26 0.66
nnet 0.69 0.22 0.67 0.11 0.31 0.87
svmRadial 0.69 0.19 0.70 0.06 0.32 0.82
LogitBoost 0.66 0.24 0.66 0.18 0.24 0.60
rpart 0.62 0.23 0.67 0.17 0.22 0.55
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Abstract
Motivation: In a predictive modeling setting, if sufficient details of the system behavior are 
known, one can build and use a simulation for making predictions. When sufficient system 
details are not known, one typically turns to machine learning, which builds a black-box 
model of the system using a large dataset of input sample features and outputs.
We consider a setting which is between these two extremes: some details of the system 
mechanics are known but not enough for creating simulations that can be used to make 
high quality predictions. In this context we propose using approximate simulations to build 
a kernel for use in kernelized machine learning methods, such as support vector machines. 
The results of multiple simulations (under various uncertainty scenarios) are used to compute 
similarity measures between every pair of samples: sample pairs are given a high similarity 
score if they behave similarly under a wide range of simulation parameters. These similarity 
values, rather than the original high dimensional feature data, are used to build the kernel.
Results: We demonstrate and explore the simulation based kernel (SimKern) concept using 
four synthetic complex systems--three biologically inspired models and one network flow 
optimization model. We show that, when the number of training samples is small compared to 
the number of features, the SimKern approach dominates over no-prior-knowledge methods. 
This approach should be applicable in all disciplines where predictive models are sought and 
informative yet approximate simulations are available.
Availability: The Python SimKern software, the demonstration models (in MATLAB, R), and 
the datasets are available at https://github.com/davidcraft/SimKern.
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Introduction and motivation
There are two general approaches to computationally predicting the behavior of complex 
systems, simulation and machine learning (ML). Simulation is the preferred method if the 
dynamics of the system being studied are known in sufficient detail that one can simulate its 
behavior with high fidelity and map the system behavior to the output to be predicted. ML is 
valuable when the system defies accurate simulation but enough data exists to train a general 
black-box machine learner, which could be anything from a linear regression or classification 
model to a neural network. In this work, we propose a technique to combine simulation and 
ML in order to leverage the best aspects of both and produce a system that is superior to either 
technique alone.
Our motivation is personalized medicine: how do we assign the right drug or drug 
combination to cancer patients? Across cultures and history, physicians prescribe medicines 
and interventions based on how the patient is predicted to respond. Currently these choices are 
made based on established patient-classification protocols, physician judgment, clinical trial 
eligibility, and occasionally limited genomic profiling of the patient. All of these approaches, in 
one way or another, attempt to partition patients into groups based on some notion of similarity.
Genomics is especially relevant for computing the similarity between two cancer patients 
since cancer is associated with alterations to the DNA, which in turn causes the dysregulation 
of cellular behavior1. Bioinformatic analysis has revealed that there is heterogeneity both 
within a patient tumor and across tumors; no two tumors are the same genomically2,3. 
Although in a small fraction of cases specific genetic conditions are used to guide therapy 
choices, for example breast (commonly amplified gene: HER2), melanoma (BRAF mutation), 
lung (EML4-ALK fusion), and head-and-neck (HPV status for radiation dose de-escalation4), 
there remains a large variability in patient responses to these and other treatments, likely due 
to the fact that patients will usually have tens or hundreds of mutations and gene copy number 
variations, chromosomal structural rearrangements, not to mention a distinct germline genetic 
state5, human leukocyte antigen type6, tumor epigenetic DNA modifications, microbiome, and 
comorbidity set. Even amidst this heterogeneity, the notion of patient similarity—although 
currently not deeply understood due to the complexities of cancer biology—is appealing both 
conceptually and for its value in the ML setting.
Simulating a drug is a task that far exceeds our current scientific capacity: it enters the patient, 
either intravenously or orally, and winds its way to the cancer cells, where it either influences the 
cancer cell via receptors on the cell membrane or penetrates into the cell and affects signaling 
pathways, cell metabolism, DNA repair, apoptosis, or some combination of these and other 
modules. Nevertheless, a vast amount of knowledge of cellular processes, residing in molecular 
biology textbooks and millions of scientific papers, has been accrued over the past century 
and it seems worthwhile to attempt to use that information, if unclear how. Most machine 
learning research efforts in the personalized medicine realm take a pure data approach. Given 
the complexity of patient biology and cancer, this approach will require vast amounts of high 
quality patient data that is suitably standardized for algorithmic processing
With this drug sensitivity prediction problem as our backdrop, we develop a method to combine 
approximate simulations with ML and demonstrate using in silico experiments that a judicious 
combination can yield better predictions than either technique alone. The basic idea is a division 
of labor: coarse and approximate simulations are used to compute similarity measures, and 
these similarity measures are then used by the ML algorithm to build a predictive model, 
called SimKern ML (Figure 1). 
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At this point in time, although vast details of cellular biology are known, we are not in a 
position to simulate with any fidelity complete cellular or in vivo cancerous processes. 
However, herein we present demonstrations that one could combine simulation results into 
machine learning and improve the overall predictive capability, a technique which may play a 
role in future drug recommendation systems.
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Figure 1. Workflow comparison of Standard machine learning (ML) and SimKern ML. The feature matrix X and 
outcome data y are given (in this paper, we generate such “ground truth” datasets by simulating complex systems, a 
step which is not shown in this figure). Traditional feature-based ML is depicted in the upper orange part. SimKern, 
the simulation-based method, pre-processes the dataset by sending each sample through a number of approximate 
simulations. Each sample pair is given a similarity score based on how closely they behave under the various 
simulations (See Figure 2 and Section SimKern simulation – similarity matrix generation for more details). This 
information is stored in a kernel matrix K where K(i,j) measures the similarity between samples i and j Note that 
K(i,i)=1 and 0 ≤ K(i,j) ≤ 1. Useful SimKern simulations yield a kernel K that improves the downstream machine 
learning performance.
Materials and methods
Our method is centered on kernelized ML. Rather than feature vectors (a list of attributes for 
each sample), kernelized learning requires only a similarity score between pairs of samples. 
For training, one needs the outcome of each training sample and a measurement of the 
similarity between all pairs of training samples. For predicting the outcome of a new sample, 
one needs to provide the similarity of that sample to each training sample. It is well known 
in ML that good similarity measures, which come from expert domain knowledge, result 
in better ML performance7. We assume that we can formulate a simulation of each sample’s 
behavior based on its known individual characteristics (i.e. features). We also assume that we 
do not know exactly how to simulate the systems, so rather than a single simulation we have 
a family (possibly parametrized by real numbers, and thus infinite) of plausible simulations. 
Two samples are given a high similarity score if they behave similarly across a wide range of 
simulations.
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We begin with a brief description of the four models we use to demonstrate and analyze the 
performance of SimKern. By describing these models, the reader has in mind a more concrete 
context with which to frame the SimKern development.
Brief model descriptions
We investigate four models: radiation impact on cells, flowering time in plants, a Boolean cancer 
model, and a network flow optimization problem. Full details and model implementation 
notes are given in the Supplementary information.
For each model we begin by generating a dataset of N samples, each sample i is described 
by a feature vector xi of length p and a response yi using the ground truth simulation (see 
Figure 1). This produces an N × p feature matrix X and a response vector y of length N. 
This ground truth simulation (referred to as SIM0 in the code repository) is not part of 
our kernelized learning method, but the datasets created are needed to demonstrate the 
simulation-based kernel ML method. This ground truth simulation step is further described 
in the Supplementary information. In an actual application of SimKern, this artificial data 
creation step would not be used.
The radiation cancer cell death model is a set of ordinary differential equations (ODEs) 
which represents a simplified view of the biochemical processes that happen after a cancer 
cell is hit by radiation. The core of the model involves the DNA damage response regulated 
by the phosphorylation of ATM and subsequent p53 tetramerization8. We have added cell 
cycle arrest terms, a DNA repair process, and apoptosis modules in order to capture the idea 
that cellular response to DNA damage involves the combined dynamics of these various 
processes. The model, which is depicted as a network graph, is displayed in Supplementary 
figure S3, and consists of 34 ODEs. The rate parameters were not tuned to realistic values 
(except for the ones from the original P53 core network, where we used the values provided 
by the authors8). Instead, values were manually chosen such that the family of samples created 
had representatives in each of the four output classes: apoptosis, repaired and cycling, mitotic 
catastrophe, and quiescence. A population of distinct cell types is formed by varying 33 of the 
ODE rate constants and the mutation status of six genes (ARF, BAX, SIAH, Reprimo, p53, and 
APAF1), for a feature vector length of 39. The SimKern simulation uses the same underlying 
model as the original ODE model with two key differences: 87 of the ODE parameters are 
marked as uncertain and given Gaussian probability distributions around their true values, 
and the simulation outputs the time dynamics of the ODEs rather than a classification.
The flowering time model is a set of six ODEs that simulate the gene regulatory network 
governing the flowering of the Arabidopsis plant9, and yields a regression problem. 19 mutants 
are modeled and experimentally validated by the authors. We use those 19 mutational states 
as well as 34 additional perturbations on the rate parameters to create a varied ground truth 
sample set. The output of the model is the time to flowering which, following the authors, is set 
to the time at which the protein AP1 exceeds a particular threshold. For the SimKern model 
we assume the same model but with uncertainty about the rate parameters. The SimKern 
simulation output is the time dynamics of the six ODEs.
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The Boolean cancer model is a discrete dynamical system of cancer cellular states10. Based 
on the steady state of the system, a sample is labelled as one of three categories: apoptotic, 
metastasizing, or other. There are no rate parameters since this is a Boolean model. We use the 
initial state vector (the on/off status of the 32 nodes in the network) as well as mutations of five 
of the genes (p53, AKT1, AKT2, NICD, and TGFβ) to create a varied sample population with 
37 features. In the SimKern simulation, we use a reduced version of the model provided in 
the original publication. It is unclear how to map the initial conditions from the full model to 
the initial conditions of the modularly-reduced model, so for all of the modules we randomly 
choose the mapping, which gives rise to the uncertainty for the SimKern simulations.  The 
output from the SimKern model (i.e. the data used to form the similarity matrix) is the same 
classification as from the ground truth model.
The network flow model is an optimization problem rather than a simulation. It falls into 
a subclass of linear optimization models called network flows which are used in a wide range 
of applications including production scheduling and transportation logistics11. The network 
flow model takes arc costs as inputs, which are the costs of sending a unit of flow through a 
certain arc in the network. The model then simulates the optimal path of flow along arcs of 
a directed graph that minimizes the total arc cost along the path. The network is designed in 
layers and is such that the flow will pass through exactly one of the three arcs in the final layer, 
which gives us a classification problem (see Figure S4). Changes in arc costs, which represent 
the features in this model, can lead to changes in the routing of the optimal flow. For the 
ground truth dataset, we generate samples by varying 12 out of the 80 arc costs. We build two 
separate SimKern simulations: the better simulation perturbs 23 arc costs, including the 12 
costs that were varied to make the ground truth dataset, resulting in a less noisy kernel. The 
worse simulation varies 21 additional arc costs resulting in a noisier kernel.
SimKern simulation – similarity matrix generation
Users must define a model (currently supported languages for the simulation modeling are 
MATLAB, Octave, and R) which simulates a sample. This simulation procedure, called SIM1 
in the python codebase, is used to generate the sample similarity kernel matrix and would 
be the starting point in an actual application of SimKern. Figure 2 illustrates the SimKern 
simulation process control.
We assume that there are parameters in this simulation model that we are uncertain about. 
Let θ be a vector of these uncertain parameters. We assume we have a random variable 
description of each of these parameters, which can be very general. For example, a parameter 
could take the value of 0 or 1 if we have two ways of modeling a particular interaction.
Then, in the simulation, depending on how that random variable gets instantiated, the code 
uses one of the two parameter values. Alternatively, we might be uncertain about the value of 
a rate constant, in which case we could use a Gaussian random variable with a specified mean 
and standard deviation. We assume independence of the random variables θ, but one could 
also assume a covariance structure.
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Each sample i = 1... N is characterized by a feature vector xi , which constitutes sample-
specific information that we use to perform the simulations; xi could be for example a genomic 
description of patient i. For r = 1... R, where R is the number of trials to run, we instantiate a 
parameter vector, θr . These parameters as well as the sample data xi are used to run simulation 
(i,r).
Let S(xi,θr) (or shorthand, Sir) be the simulation output for sample i with uncertainty 
parameters equal to θr . Note that these outputs S(xi ,θr ) can be scalars, a classification category, 
vectors, or any other object. There is no need for these outputs to be the same as what we are 
trying to predict, yi . We simply assume that given two such outputs, say Sir and Sjr for samples 
i and j, we have a way to measure the similarity between them. Let this similarity be given by 
z(i,j,r). We leave it up to the user to define this function in general (a concrete procedure, for 
simulations using ordinary differential equations, is given in the Supplementary information).
Finally, the similarity K(i,j) between two samples i and j is the average similarity across the 
simulation runs:
𝐾𝐾(𝑖𝑖𝑖 𝑖𝑖) =
1
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𝑅𝑅
𝑟𝑟𝑟𝑟
∑ 𝑧𝑧(𝑖𝑖𝑖 𝑖𝑖𝑖 𝑧𝑧) 
. 
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𝑡𝑡𝑟𝑟𝑡𝑡𝑡𝑡 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑟𝑟 𝑡𝑡𝑡𝑡 𝑡𝑡𝑡𝑡𝑡𝑡𝑠𝑠𝑡𝑡𝑡𝑡𝑡𝑡
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𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑓𝑓 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑧𝑧𝑠𝑠𝑠𝑠
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∑𝑡𝑡(𝑦𝑦𝑦𝑡𝑡 − 𝑦𝑦𝑡𝑡)
2
∑ (𝑦𝑦𝑦 − 𝑦𝑦𝑡𝑡)2𝑡𝑡
The above SimKern kernel matrix generation procedure is implemented in Python and is fully 
described in the Supplementary information.
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Figure 2. Creation of the similarity matrix for use downstream in the machine learning.
Machine learning comparisons procedure
Figure 1 shows a schematic of the differences in the data processing and machine learning 
steps for Standard ML and SimKern ML. We compare standard feature-based ML algorithms 
(orange/top: linear support vector machine (SVM), radial basis function (RBF) SVM, and 
random forest (RF)) with simulation kernel based methods (green/bottom: kernelized SVM 
and kernelized RF). We also include results for 1-nearest neighbor (NN) and kernelized 
1-nearest neighbor (SimKern NN). As NN-type algorithms are arguably the simplest non-
trivial ML algorithms, including these algorithms allows us to understand the distinct 
contributions of ML algorithm sophistication and simulation-based kernels.
Since we can generate as many samples as we wish, we train the models and tune the 
hyperparameters on training and validation datasets which are distinct from the final testing 
set on which we compute prediction performance metrics (see section Performance metrics). 
The ground truth simulation generates one dataset which is then split into three parts (train/
validation/test) using the standard proportions 50%/25%/25%12, p.222.
Run simulation for 
sample 1
Run simulation for 
sample 2
Compute similarity matrix 
K(i,j)  i,j
Compute pairwise similarities 
z(i,j,r) 
   i,j Є {1, ... , N}, i ≠ j
Randomize simulation 
conditions (instantiate θr) 
Run simulation for 
sample N
For r = 1, ... R
SimKern simulation
A
A
N × N 
similarity matrix
Feature vectors 
1, ..., N
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SVM13 and NN algorithms are dependent on feature scaling, therefore, features are 
standardized to the interval  by subtracting the minimum value and scaling by the range. 
Categorical features are dummy-coded for SVM and NN algorithms.
Each ML algorithm is trained on the training data for many hyperparameter configurations 
and the configuration with the best fit on the validation data is selected. The model given the 
selected configuration is applied on the test set to compute the performance metrics. See Alg. 
1 in the Supplementary information for the details of training, hyperparameter tuning, and 
testing procedures.
To investigate the performance of simulation-based kernels in scenarios with less data 
for training, we consider five scenarios in which we train the algorithms on subsamples 
comprising of the training data. The subsampling percentages are chosen differently per 
model to highlight the interesting regions of curves that display the performance versus 
training set size. Table S3 reports the subsampling percentages per model.
Performance metrics
For each of the simulation models, we estimate the generalization performance of an ML 
algorithm in test data, i.e. data unused for model training, as performance estimates on 
training data are of little practical value12, p.230.
The learning tasks per model are either classification or regression. For classification, we 
consider prediction accuracy, which is defined as
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where TP, TN, FP, FN are the counts of true positives, true negatives, false positives, and false 
negatives, respectively.
For regression, we consider the coefficient of determination R2, which is defined as
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where y1 is the outcome for sample i, ŷi is the predicted outcome for sample i, and y ̅ is the 
sample mean of the outcome.
To attain a reliable estimate of the generalization performance, we consider the average test 
data performance in ten repetitions of a train/validation/test analysis, i.e. repeating training 
and hyperparameter tuning each time.
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Standard ML vs. SimKern ML comparison
For each model, we produce a box plot and/or a line plot that show algorithm performance 
versus training dataset size for the various ML algorithms in both algorithm groups, Standard 
ML and SimKern ML.
1. Box plots display results for each algorithm separately for the Standard ML (linear 
SVM, RBF SVM, RF, NN) and SimKern ML algorithms (SimKern SVM, SimKern RF, 
SimKern NN). The horizontal lines indicate the sample median, the boxes are placed 
between the first and third quartile (q1,q3). Outliers are defined as samples outside 
[q1-1.5(q3-q1),q3 + 1.5(q3-q1)] and are indicated by crosses.
2. Line plots further condense the findings by displaying the median performance metric 
of the best performing Standard ML and SimKern ML algorithms, excluding NN 
algorithms in both cases. The best performing algorithm is defined as the algorithm that 
most frequently produces the highest median performance metric over all five training 
dataset subsamples. Lines are interpolated for visual guidance.
Sensitivity analysis
To investigate possible factors affecting the SimKern algorithms’ prediction performance, we 
run the following sensitivity analyses:
Varying prior knowledge
1. Radiation model: we examine the results for two kernels which represent different levels 
of prior knowledge. Both cases utilize the same SimKern simulation, but the higher 
quality kernel uses the dynamics of only the compartments of the ODE set that are used 
in the classification of the samples in the initial ground truth simulation. The lower 
quality kernel uses all ODE equations, therefore not emphasizing the most important 
ones14.
Varying simulation parameter noise/bias
2. Network flow model: we generate two kernels for the network flow model. These kernels 
differ in the number of arc costs that are perturbed and the size of the perturbations (full 
details in Supplementary information).
3. Flowering time model: along with the model that generates the baseline kernel, we 
study one less noisy, one noisier, and one biased version of the SimKern simulation. 
The baseline SimKern simulation uses multiplicative Gaussian noise on 34 of the rate 
parameters, using a mean of 1 and a standard deviation of 0.2. The less noisy model uses 
stdev=0.1 and the noisier model uses stdev=0.4. For a more radical, and non-centered, 
departure from the true rate parameters, we also run a model where we multiply each of 
the same 34 rate parameters with a random variable chosen uniformly from the discrete 
set {0.01,1,5,10}.
Varying the number of simulation trials, R
4. Network flow model: we analyze the effect of additional simulation trials on the prediction 
performance. We compare the prediction performance of SimKern algorithms when using 
a similarity kernel based on R = 3 simulation trials to the final kernel based on R = 10 trials. 
Furthermore, we track the convergence of the kernel matrix over R = 10 trials.
SIMULATION ASSISTED MACHINE LEARNING 95
5
Results
The general theme that emerges is that, for small training dataset sizes, the methods using the 
SimKern kernel outperform the Standard ML methods. For larger training sizes, however, the 
standard methods either approach the SimKern methods or exceed them, depending on the 
quality of the kernel.
For the radiation model, we see exactly this general pattern (Figure 3). For small training 
sizes (up to 50 samples), the SVM with the SimKern kernel dominates. We can attribute much 
of the performance gain to the similarity kernel itself given that the NN algorithm using the 
same similarity kernel also dominates over the no-prior-knowledge methods for all training 
sizes shown. The increase in accuracy by the Standard ML algorithms does not yet show 
signs of saturation by 500 training samples. These box plots are summarized by line plots in 
Figure 7 (left), which also displays the results of the lower quality SimKern kernel, which was 
made with the same simulations but without focusing on the most relevant ODEs for the 
kernel matrix computation.
Figure 3. Machine learning results for the radiation cancer model. NN = nearest neighbor, RF = random forest, 
SVM = support vector machine, RBF = radial basis function.
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Figure 4. Machine learning results for the flowering time model. NN = nearest neighbor, RF = random forest, SVM 
= support vector machine, RBF = radial basis function.
Figure 5. Machine learning results for the Boolean cancer model. NN = nearest neighbor, RF = random forest, SVM 
= support vector machine, RBF = radial basis function.
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Figure 6. Varying simulation trials experiments for the network flow model. The upper two box plots compare the 
learning accuracy for a kernel from the third of R = 10 trials versus the final kernel. The kernels themselves are 
displayed with the same color scale below, and centered at bottom displays the convergence of the kernel (measured 
using the Frobenius matrix norm) over the ten trials. NN = nearest neighbor, RF = random forest, SVM = support 
vector machine, RBF = radial basis function.
The results of the flowering time model, which also display the clear dominance of SimKern 
learning for small training data set sizes, show a trend of decreasing variance in predictive 
performance with increasing training sizes (Figure 4). SimKern learning is strongly dominant 
up to 75 training samples, after which the two learning styles converge to R2 ≈ 1. Another view 
of the improvement offered by the SimKern method for small training size set sizes is shown 
by plotting the predicted flowering times versus the actual flowering times, Figure S9.
The sensitivity results obtained by increasing the variance of the (centered) Gaussian 
noise that was applied to the flowering model’s rate parameters display a robustness to these 
deviations (Figure 8, upper green curves and Gaussian box plots). However, the non-centered 
noise perturbation analysis shows a clear drop in ML accuracy (Figure 8, dark green dotted 
line and dark green box plot). With enough training data, all SimKern kernels, including the 
ones with heavy noise, achieve an R2 above 0.95. We call such kernels sufficient.
In contrast, the Boolean cancer model kernel is based on a model reduction with additional 
uncertainty and produces what we call a biased kernel. There, the SimKern approach produces 
an accuracy that initially dominates but quickly plateaus to around 85% and is overtaken by 
no-prior-knowledge methods when more training data is available (Figure 5). The fact that 
the kernel learning barely improves with additional data implies that the feature space induced 
by the simulation kernel is simple enough to be learned by a small amount of samples15. The 
kernelized NN method gets worse with more samples, and in general is worse than the other 
SimKern algorithms, which indicates that the space induced by the biased kernel is less cleanly 
separable compared to the flowering model case. Above 100 training samples, the no-prior-
knowledge RF method is the superior technique.
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Figure 7. Varying prior knowledge experiments for the radiation model (left) and varying parameter noise 
experiments for the network flow model (right). Performance metrics of SimKern ML based on simulations with 
less and more prior knowledge (green) and Standard ML (orange). For each line, the best performing algorithm of 
SimKern ML or Standard ML is selected (see section Standard ML vs. SimKern ML comparison). Note, the waviness 
of the less noise case for the network flow model is an artifact of how the data from the box plots was converted into 
a line plot; the full data, Figure S7, reveals a flat relationship.
Figure 8. Varying simulation parameter noise/bias experiments for the flowering time model. SimKern ML based on 
simulations with varying parameter noise (green), with parameter bias (dark green), and Standard ML (orange). Left: 
performance metrics of SimKern ML (green) and Standard ML (orange) trained on up to 150 samples. For each line, 
the best performing algorithm of SimKern ML or Standard ML is selected (see section Standard ML vs. SimKern ML 
comparison). Right: performance metrics box plots for the 25 training sample case.
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For the network flow problem we evaluate two separate kernels (Figure 7, right) based on 
different levels of noise in the SimKern simulation: the kernel based on a less noisy SimKern 
simulation dominates throughout, but even the kernel based on a noisier SimKern simulation 
is still useful in the very small training set size range. It is doubtful whether one can make 
general statements about how good a simulation needs to be in order to yield a useful kernel.
However, the intuition that the simulations need only discover the similarity of samples, while 
not necessarily providing accurate (hence directly useful) simulation results, is described in 
Figure S8.
When comparing the individual Standard ML algorithms to the SimKern ML algorithms 
based on the noisier SimKern simulation (Figure S7), Standard RF eventually dominates. 
When comparing algorithms within the Standard ML group, RF is the dominant Standard 
ML algorithm for the network flow model (Figure S7) as well as for the Boolean cancer 
model (Figure 5). For these models, the dominance of RF is likely related to the discrete 
characteristics of the underlying models.
The quality of a simulation-generated kernel also depends on the number of trials  that are 
used to compute the kernel. Figure 6 displays both the convergence of the kernel (bottom) 
and the improved learning accuracy from the further converged kernel (top), for the less 
noisy network flow case. We see that the earliest kernel written, kernel three (we chose to not 
determine similarity kernels below R = 3), performs noticeably worse than the final kernel. We 
can also visually observe the differences in the kernels by plotting the 500×500 kernels (Figure 
6, bottom left and right). The kernel convergence plot is obtained by taking the Frobenius 
norms of the difference of the kernel matrices of iteration i - 1 and i, until i = R(=10).
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Discussion
We introduce simulation as a pre-processing step in a machine learning pipeline, in 
particular as a way to include expert prior knowledge. One can consider simulation as a 
technique which regularizes data or as a specialized feature extraction method. In either 
view, the SimKern methodology offers a decomposition of an overall ML task into two steps: 
similarity computation followed by predictive modeling using the pairwise similarities. This 
decomposition highlights that to improve the performance of an ML model one can direct 
efforts into determining better similarity scores between all samples. This is in contrast to 
the more commonly heard call for “more data” to achieve better ML results. Of course, more 
samples are always desirable, but here we show that, particularly in limited data settings, 
sizable performance gains can come from high quality similarity scores.
The decomposition of simulation and machine learning steps also points out their individual 
contributions. The simulation-based kernel structures the space in which the samples live (or 
more technically, the dual of the space16), and ML finds the patterns in this simplified space. 
We see that in order to improve machine learning performance we can either improve the 
kernel or increase the number of samples to better populate the space. For the cases shown 
here, custom similarity measures show large improvements especially in limited data settings 
(up to a 20% increase in classification accuracy and a 2.5 fold increase in R2, depending 
on the case and the amount of training data used). One could also use the output of the 
simulations as features for machine learning rather than the additional kernelization step that 
we employed. Using the simulation outputs directly is related to the field of model output 
statistics from weather forecasting, where low level data from primary simulations are used as 
inputs to a multiple regression model which outputs human-friendly weather predictions17. 
In our case, we opted for kernelizing the simulation outputs to highlight the fundamental 
concept of similarity and because a similarity computation is natural when the output of the 
simulations is a set of time varying entities, e.g., in the case of ODEs.
Similar in spirit to SimKern, although differing in details, combining simulation and 
machine learning has been used in physics to predict object behaviour18,19. Simulation results 
are used to train networks to “learn” the physics. Varying the simulation conditions during 
training, called domain randomization, is used to improve model generalization20. Inversely 
to the SimKern approach to exploit simulation to enhance ML algorithms, machine learning 
is also used to correct the inputs to physics simulations21, an idea which is also pursued in the 
context of traffic prediction22.
A novel potential application of the SimKern methodology, one that the authors are currently 
investigating, involves the prediction of peptides (chains of approximately nine amino acids) 
binding to a given human leukocyte antigen (HLA) class 1 allele. Current technologies 
(e.g.,23) predict if a given peptide will bind to a given HLA allele using properties of the amino 
acids but without using 3D details of the chemical structure of the peptide or information 
on the structural binding of the peptide and HLA molecule. Computational predictions of 
binding are considered too difficult at the present time due to the sensitivity of the structural 
conformations to the detailed chemistry of peptides and the non-covalent interactions24. 
Nevertheless, simulations could be used to generate similarity scores between peptides, and 
then the supervised binding data can be used to train a kernelized classification algorithm.
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Finally, the use of a SimKern kernel need not be an all-or-nothing decision, since two or more 
kernels can be combined to yield a single kernel. This allows one to explore the combination 
of “standard” kernelized learning (using uninformed kernels such as linear or RBF) with a 
SimKern kernel. In the case of a weighted linear sum as the method of kernel combining, 
one can optimize the weighting vector as part of the training procedure7. Combining kernels 
allows one to mix traditional feature-based machine learning (which we called Standard ML 
above) with prior knowledge similarity matrix-based learning.
Conclusions
It remains to be seen which approaches will be the most fruitful as we make our way towards 
personalized cancer medicine. Direct testing of chemotherapeutic agents on biopsied patient 
tissues is a straightforward and promising “hardware-based” approach25. In the machine 
learning realm, expert feature selection may turn out to be more feasible than the simulation-
based kernel methods described in this report. A key question is: can we make simulation-
based kernels that—although almost certainly biased—will still be useful (see, e.g., Figure 7)? 
Progress in detailed biological simulation, such as the full simulation of the cell cycle of 
the bacterium Mycoplasma genitalium26, the OpenWorm project27, and integrated cancer 
signaling pathways for predicting proliferation and cell death28 offer some encouragement, 
but cancer influences human biology at all levels, from minute phosphorylations to immune 
system rewiring. It is thus by no means clear if we are close to simulations that can be useful 
in this context. However, the magnitude of the problem—both in economic terms and for 
the number of future patients at stake—suggests pressing forward on all fronts that display 
conceptual promise.
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Supplementary information
Ground truth and SimKern simulations
The simulation framework, which handles the generation of ground truth data as well as 
the SimKern module which performs the simulations and computes the similarity matrix, 
is written in Python, and supports simulation models written in MATLAB, Octave, and 
R. It uses text file communication so it could be easily adapted to simulations written in 
other languages. The Python package, SimKern, is available at github: https://github.com/
davidcraft/SimKern. We refer to the ground truth simulation as SIM0 and the SimKern 
simulations as SIM1. This naming convention is also reflected in the Python code base.
The various code modules are summarized in Table S1.
Table S1. Code module descriptions.
Name Functionality Requires Language
Groundtruth dataset 
generation
(“SIM0”)
Generates datasets 
(features and known 
outcomes) with 
user-selected 
number of samples
The simulation 
(“SIM0”) model (*.t 
file)
Python (simulation 
models though are 
in Matlab, octave, or 
R)
SimKern
(“SIM1”)
Handle running 
families of 
simulations, 
aggregating results 
and forming the 
similarity kernel 
Feature vectors that 
are used to simulate 
each feature 
(“genome key” files), 
and the master *.u 
file that contains the 
stochasticity 
information 𝛉𝛉
Python (as above)
Machine Learning 
Comparison 
Tune and train 
models with all 
machine learning 
algorithms on 
various dataset 
sizes for comparison
Sample features for 
standard machine 
learning, sample 
similarity matrix for 
kernelized learning, 
and sample 
outcomes
Matlab (also 
available in the 
SimKern python 
repository, but 
Matlab version used 
for the results in the 
paper)
Ground truth data generation procedure: SIM0
A simulation model file used to create a ground truth dataset has the suffix .t. A file used to 
create the SimKern family of simulations is suffixed with .u (see next section). These model 
files are in the language of the system used to run the simulations and have entities that are set 
off by dollar signs. These entities are the parameters to vary from one sample to the next, for 
the ground truth dataset generation, or from one trial to the next, for the SimKern generation. 
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As an example, if diff erent samples may have diff erent values for a rate parameter called k1, a 
line in the simulation fi le could read:
k1 = $gauss(8,2, name=‘decayConstant1’)$;
Th e Python code will replace the text set off  by the dollar signs with a random variable drawn 
from a Gaussian distribution with mean 8 and standard deviation 2. In the fi le storing the 
sample features that gets written, this feature will be named decayConstant1. Th is same style 
is used for both SIM0 and SIM1. Th e distributions that are allowed, and more usage details, 
are given in the manual on the SimKern github repository.
If the simulation package to use is MATLAB, the Python package allows a direct process 
hook via a MATLAB-Python API provided by MathWorks. Th is speeds up the overall runtime 
by not requiring the expensive startup time of MATLAB for every run.
Let N be the number of samples we generate for the SIM0 dataset. Let the feature vectors 
(the parameters that make the samples diff erent from each other) be given by the vectors
xi,i = 1, ..., N. Each xi vector is a vector of length p, where we are following the standard 
machine learning notation where p equals the number of features. Let yi denote the outcome 
of the simulation, which could be a category (e.g. alive or dead) or a real number. Since we 
generate these outputs via a simulation, viewing that simulation as a function S0 we can 
write yi = S0(xi). Th e ground truth data generation procedure is depicted in Figure S1.
Figure S1. Ground truth data generation procedure, SIM0.
106 SIMULATION ASSISTED MACHINE LEARNING
The x data get written to Sim0Genomes.csv and the  data to Sim0Output.csv (the term genome 
is used since the use case that provides the motivation for this software is machine learning 
for biological systems where the feature vector is based on genomics). Separate files, called 
genome keys, are written out for each sample for use in the SIM1 runs.
Similarity kernel generation: SIM1
The main document describes the similarity matrix computation.
The python software handles writing out and running the individual (i, r) run files, using the 
.u file as the template. This .u file must reference another file which specifies the parameters 
from the SIM0 run that make each individual sample i distinct. This file is called genome1_
key (the “1” is replaced automatically by the SIM1 python code with the sample number i).
The output of this procedure is the similarity matrix, given in a file called SimilarityMatrixfinal.
csv. A similarity matrix is also written after every trial (from the third trial onward; similarity 
matrices before the third trial are considered not converged yet and so are not written out).
Similarity as measured by closeness of ODE solutions
A typical setting for a SIM1 run will be the simulation of a set of ordinary differential equations 
(ODEs). In this context, the similarity between population members i and j, for simulation 
r, can be a measure of how close the overall time dynamics for i are to the time dynamics of 
j, e.g., represented by the mean squared error over discrete time points. More specifically, 
assume the ODE simulation contains E different entities (e.g. protein levels), in other words  E 
ODEs. Let us further assume that the simulation program outputs the levels of these entities at 
a given set of times, t1,t2,...,tK,...,tT. Let Lri be the level of ODE entity e at time tK , for population 
member i under simulation r. Since the ODE equations may be of different magnitudes, we 
will normalize each pair being compared by the maximum level that either ever takes over 
the time course (we are implicitly assuming the ODEs solutions are always non-negative, this 
would have to be modified for negative levels). For the pair of samples (i, j) and for entity e in 
simulation run r, the maximum value M is given by:the maximum value 𝑀𝑀𝑀𝑀  is given by: 
 
𝑀𝑀𝑀𝑀(𝑖𝑖𝑖𝑖, 𝑗𝑗𝑗𝑗, 𝑒𝑒𝑒𝑒, 𝑟𝑟𝑟𝑟)  =  𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚[𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑘𝑘𝑘𝑘𝐿𝐿𝐿𝐿𝑟𝑟𝑟𝑟𝑖𝑖𝑖𝑖 (𝑒𝑒𝑒𝑒, 𝑘𝑘𝑘𝑘),𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑘𝑘𝑘𝑘𝐿𝐿𝐿𝐿𝑟𝑟𝑟𝑟𝑗𝑗𝑗𝑗 (𝑒𝑒𝑒𝑒, 𝑘𝑘𝑘𝑘)] 
 
With these definitions, we can write 
 
𝑧𝑧𝑧𝑧(𝑖𝑖𝑖𝑖, 𝑗𝑗𝑗𝑗, 𝑟𝑟𝑟𝑟)  =  1 −  1
𝐸𝐸𝐸𝐸 ∗ 𝑇𝑇𝑇𝑇
�� �
𝐿𝐿𝐿𝐿𝑟𝑟𝑟𝑟
𝑖𝑖𝑖𝑖 (𝑒𝑒𝑒𝑒 , 𝑘𝑘𝑘𝑘) − 𝐿𝐿𝐿𝐿𝑟𝑟𝑟𝑟𝑗𝑗𝑗𝑗 (𝑒𝑒𝑒𝑒, 𝑘𝑘𝑘𝑘)
𝑀𝑀𝑀𝑀(𝑖𝑖𝑖𝑖, 𝑗𝑗𝑗𝑗, 𝑒𝑒𝑒𝑒, 𝑟𝑟𝑟𝑟) �2𝑇𝑇𝑇𝑇
𝑘𝑘𝑘𝑘=1
𝐸𝐸𝐸𝐸
𝑒𝑒𝑒𝑒=1
 
 
Finally, in addition to normalizing the ODE solutions to a maximum value of 1, the user 
may want to 
weight the different entities 𝑒𝑒𝑒𝑒 to express the prior knowledge that some entities are more 
important 
for similarity considerations than others. Let $ 0 ≤ 𝑤𝑤𝑤𝑤𝑒𝑒𝑒𝑒 ≤ 1 be user-defined weights and 
then we 
have: 
𝑧𝑧𝑧𝑧(𝑖𝑖𝑖𝑖 , 𝑗𝑗𝑗𝑗, 𝑟𝑟𝑟𝑟)  =  1 −  1
𝐸𝐸𝐸𝐸 ∗ 𝑇𝑇𝑇𝑇
�𝑤𝑤𝑤𝑤𝑒𝑒𝑒𝑒 ��
𝐿𝐿𝐿𝐿𝑟𝑟𝑟𝑟
𝑖𝑖𝑖𝑖 (𝑒𝑒𝑒𝑒, 𝑘𝑘𝑘𝑘) − 𝐿𝐿𝐿𝐿𝑟𝑟𝑟𝑟𝑗𝑗𝑗𝑗 (𝑒𝑒𝑒𝑒, 𝑘𝑘𝑘𝑘)
𝑀𝑀𝑀𝑀(𝑖𝑖𝑖𝑖 , 𝑗𝑗𝑗𝑗, 𝑒𝑒𝑒𝑒, 𝑟𝑟𝑟𝑟) �2𝑇𝑇𝑇𝑇
𝑘𝑘𝑘𝑘=1
𝐸𝐸𝐸𝐸
𝑒𝑒𝑒𝑒=1
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With these definitions, we can write 
 
𝑧𝑧𝑧𝑧(𝑖𝑖𝑖𝑖, 𝑗𝑗𝑗𝑗, 𝑟𝑟𝑟𝑟)  =  1 −  1
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Finally, in addition to normalizing the ODE solutions to a maximum value of 1, the user 
may want to 
weight the different entities 𝑒𝑒𝑒𝑒 to express the prior knowledge that some entities are more 
important 
for similarity considerations than others. Let $ 0 ≤ 𝑤𝑤𝑤𝑤𝑒𝑒𝑒𝑒 ≤ 1 be user-defined weights and 
then we 
have: 
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Finally, in addition to normalizing the ODE solutions to a maximum value of 1, the user 
may want to weight the different entities e to express the prior knowledge that some entities 
are more important for similarity considerations than others. Let 0 ≤ we ≤ 1 be user-defined 
weights and then we have:
the maximum value 𝑀𝑀𝑀𝑀  is given by: 
 
𝑀𝑀𝑀𝑀(𝑖𝑖𝑖𝑖, 𝑗𝑗𝑗𝑗, 𝑒𝑒𝑒𝑒, 𝑟𝑟𝑟𝑟)  =  𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚[𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑘𝑘𝑘𝑘𝐿𝐿𝐿𝐿𝑟𝑟𝑟𝑟𝑖𝑖𝑖𝑖 (𝑒𝑒𝑒𝑒, 𝑘𝑘𝑘𝑘),𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑘𝑘𝑘𝑘𝐿𝐿𝐿𝐿𝑟𝑟𝑟𝑟𝑗𝑗𝑗𝑗 (𝑒𝑒𝑒𝑒, 𝑘𝑘𝑘𝑘)] 
 
With these definitions, we can write 
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Finally, in addition to normalizing the ODE solutions to a maximum value of 1, the user 
may want to 
weight the different entities 𝑒𝑒𝑒𝑒 to express the prior knowledge that some entities are more 
important 
for similari y considerations than oth rs. Let $ 0 ≤ 𝑤𝑤𝑤𝑤𝑒𝑒𝑒𝑒 ≤ 1 be user-defined weights and 
then we 
have: 
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𝐸𝐸𝐸𝐸
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Machine learning algorithm comparisons procedure
Machine learning (ML) was conducted in MATLAB (MathWorks, Natick, MA, USA) using 
the libSVM package for all SVM models1. The python SimKern codebase also provides 
routines for the machine learning runs. Alg 1 outlines the experimental design to tune the 
hyperparameters and then estimate performance metrics for each ML algorithm. Although 
the algorithm initially splits a dataset into three pieces—50% for training, 25% for validation, 
and 25% for final accuracy assessment—the training subset is further subsampled to assess 
how accuracy depends on the amount of training data for the various models and machine 
learning algorithms. The same experiment is repeated for each dataset. The procedure is 
outlined below and explained in detail in the subsequent subsections.
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Alg. 1. Experimental design to estimate ML performance (this algorithm is executed independently on each dataset). 
A is the set of ML algorithms used. s1 subsampling percentages vary by model in order to home in on the most 
relevant part of the curve which represents accuracy versus amount of training data, see Table S3.
Stratifi cation
For the classifi cation models, the data is split while approximately stratifying for classes. 
Stratifi cation of classes in training, validation, and test data ensures stability in the estimation 
process. Consider the case where random sampling led to an unusual distribution of classes 
in training and validation data. Consequently, the test data would very likely have a class 
distribution diff erent than the training data. Classifi ers not correcting for class imbalance 
(default RF and default SVMs) that are trained on this training data would perform worse 
on the test data. Since we want to estimate generalization performance, i.e. performance on 
the general population with a class distribution estimated by the class distribution in the full 
dataset, we stratify classes in training and test data.
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Hyperparameter tuning
Th e performance of the studied ML algorithms is dependent on algorithm-specifi c 
hyperparameters (HP) whose optimal values for generalization performance are not known a 
priori. HPs are tuned by a grid search: for a selection of values per HP, the algorithm is trained 
on the training data and evaluated on the validation data for each possible HP combination. 
Th e HP combination with the best performance metric in the validation data is selected. Table 
S2 lists the HPs that are tuned, their ranges, and values on the search grid for each algorithm. 
Values are partly determined from existing literature or chosen experimentally. HPs not 
mentioned here are set to default values. Values for SVM parameters are partially taken from2. 
For RF, the number of trees is fi xed at 100.
While Breiman (2001)3 did not limit the number of terminal nodes in a tree, Duroux and 
Scornet (2016)4 provide empirical evidence in favor of tuning. Th erefore, we tune the maximal 
number of splits allowed in a tree. Tuning grid boundaries have been extended manually 
to reduce the number of cases where the tuning procedure selects HP values on the grid 
boundaries, which would suggests that better HP values might be found outside the grid.
Table S2. Hyperparameter tuning per algorithm. C is the weight corresponding to training set error in the SVM 
objective. ε (only used for SVM regression) determines the width of the margin enclosing the separating hyperplane 
in SVM regression. γ is a parameter of the RBF kernel K(x,y) = e(-γ||x-y||2). n. feat. is the number of randomly sampled 
features compared at each split in a tree. n. splits is the maximal number of splits per tree, grid values exceeding the 
[1, (n - 1)]interval  are truncated to the boundary. n is the number of training samples, p is the number of features.
Table S3. Subsampling training percentages per model.
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Machine learning algorithms
We compare standard machine learning algorithms that use the ground truth feature vectors 
(Standard ML algorithms) to ML algorithms that use the SimKern kernel matrix (SimKern
ML algorithms), see Figure 2. For the Standard ML learning, we utilize three established ML 
algorithms: linear SVM5, radial basis function (RBF) SVM, and random forest (RF)3. For 
SimKern learning, we use SVM with the similarity matrix as a custom kernel (note that for 
the SVM algorithm the kernel matrix, also known as the Gram matrix, has to be symmetric 
positive defi nite, which in all of our models is the case, and indeed is required by the libSVM 
soft ware) and the random forest algorithm with the similarity matrix as the feature matrix 
input6. Th is random forest, called SimKern RF, classifi es new samples according to their 
similarities with training samples.
Additionally, we compute nearest neighbor predictions to compare to the more advanced 
machine learning algorithms. For the Standard ML case, we use a 1-NN algorithm on the 
SIM0 feature vector. For the SimKern case, we use the label of the most similar distinct 
training sample according to the similarity matrix. We label this approach SimKern NN.
Figure S2. An overview of the data handling procedures for the various machine learning algorithms used. 
SVM=support vector machine, RBF=radial basis function, ML=machine learning, NN=nearest neighbors, 
RF=random forest.
SIMULATION ASSISTED MACHINE LEARNING 111
5
Model descriptions
Table S4 gives a summary of the machine learning problem sizes, number of features, and 
other attributes, for the four models.
Table S4. Numerical information for the four models. Class distribution per model for the ground truth (SIM0) 
dataset. Note that the Flowering model has continuous outcomes (i.e. fl owering time) and the Boolean and Network 
models have only three classes. Classes (in order 1, 2, 3, 4) for the Radiation model are apoptosis, repaired and 
cycling, mitotic catastrophe, and quiescence. For the Boolean cancer model they are apoptosis, metastasis, and other. 
For the Network model they are simply which of the exit arcs the optimal solution fl ows through. n is the number of 
samples generated for the SIM0 ground truth dataset, p is the number of features in the ground truth dataset, and R
is the number of trials run in the SimKern step. *For the fl owering model one of the features is a categorical variable 
of 19 classes, representing 19 diff erent mutational states. Th us if one-hot encoded this would lead to an additional 
19 features.
Radiation model
Th e radiation model is built up as four connected modules. We opt to not simulate the cell 
cycle and instead focus on the chain of events that happens aft er radiation damages a cell’s 
DNA: DNA repair (modeled at a high level), p53-based transcription factor control, cell cycle 
arrest, and apoptosis, see Figure S3. Although highly simplifi ed, this model recapitulates the 
idea that the inter-connected dynamics of these processes determine cell fate aft er radiation 
damage.
Tuning this model to refl ect the behavior of an actual cell line is very large task, and probably 
not possible in any realistic way, since the genes (proteins) chosen to be in the model are but a 
small subset of the proteins involved in a DNA repair and cell cycle control cascade. However, 
even without validated rate constants chosen, the model provides a numerical instance of a 
complex system, based on known biology, where diff erent modules (biochemical processes) 
are involved in determining the fate of a cell subject to an external stimulus. We hand tuned 
the parameters of the base model. Th ere are many parameters to choose from, and our choices 
were from manual explorations which led to a set of parameters that led to diverse system 
behavior (some samples ending in apoptosis, others in cell cycle arrest, etc.).
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Figure S3. A model of entities and processes involved in cell fate decision following radiation. Th e gray nodes 
depict the process of DNA breakage and repair. DNA breaks send signals via ATM to the p53-MDM2-ARF module 
(purple), which in turn sends both apoptotic signals (orange) and cell cycle arrest signals (blue). Th e cancer genes 
MYC and Rb (green) are modeled as fi xed parameters rather than time varying entities. Th e fi rst letters of each oval 
have the following meanings: P = protein, M = mRNA, K = rate constant, O = other. Phos stands for phosphorylated.
Th e p53-MDM2 transcription regulatory control circuit comes from EliaŠ et al. (2014)7.
We use the single compartment version of the model, where the specifi c location of molecules 
(nucleus versus cytoplasm) is ignored. Radiation damage aff ects this circuit via the ATM 
kinase pathway, which increases the phosphorylation and hence stability of p53. p53 then 
goes on to be a transcription factor for apoptosis and cell cycle arrest genes.
Cell specifi c alterations (mutations, amplifi cations, deletions) for MYC, RB1, and p53 
interact to infl uence how the p53-MDM2 circuit behaves, which in turn aff ects the behavior of 
the downstream processes of cell cycle arrest and apoptosis. Th e number of cell cycle controls 
in an eukaryotic cell is large. Rather than attempting to model most of them, we choose a few 
overlapping controls to create a model that creates a challenging machine learning problem.
Apoptosis is modeled as the competition between pro-apoptotic (BAX, FasL) and anti-
apoptotic proteins (BCL-2, BCL-xl). Apoptosis occurs if the apoptosome is formed (a 
combination of cytochrome c and APAF-1, which together release caspases from the 
mitochondrial membrane) or via the extrinsic Fas/FasL pathway.
Th e detailed mathematical model is given next. In the ODE equations as written below, we 
use a generic “k” for ODE constants, to reduce clutter. For the full details, we refer the reader 
to the MATLAB code.
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Phosphorylated nuclear p53 protein tetramerizes to form its active transcription factor state. 
For convenience we define the p53 tetramerized term as:
p53tt = (MUTp53 * pP53NucPhos4)
The mutation coefficient MUTp53 is a uniform random variable between 0 and 1, reflecting the 
idea that there are a large number of p53 mutations that potentially affect the tetramerization 
in varying ways.
The full ODE model is given here:
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Th e initial condition of the system is an externally applied radiation dose modeled by setting 
oRadiation(0) = 1 followed by an exponential decay. Th e only other non-zero initial condition 
is for ECDK2 since at time 0 we assume that there are no brakes on the cell cycle.
Additional modeling notes
Cells have many mechanisms to control cell growth and division. We choose to model just 
a few, and in a simplifi ed manner, to get the fl avor of the complexity. We split the control 
into two cases, one where the Rb gene is functioning (Rb = 1) and one where the Rb gene is 
impaired (Rb = 0). For the Rb = 0 case, a way to arrest cell growth is via the SIAH or Reprimo 
gene pathways. SIAH and Reprimo are activated by a functioning p53 danger signal pathway, 
and we model their eff ect on the arrest signal as additive. Th us:
Case Rb = 0:
𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 𝑜
1
; 
1 + 𝑜𝑜𝑘𝑘𝑘𝑘1∗(𝑥𝑥(𝑆𝑆𝑆𝑆𝑘𝑘𝑆)+𝑥𝑥(𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑆𝑆𝑅𝑅𝑅𝑅)−𝑘𝑘𝑘𝑘2)
Case 𝑅𝑅𝑅𝑅 𝑜 1: 
𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜λlow ∗ 1 + (1 − 𝜆𝜆𝑙𝑙𝑅𝑅𝑙𝑙)
1
1+𝑅𝑅𝑘𝑘𝑘𝑘1∗(𝑥𝑥(𝑆𝑆𝑆𝑆𝑘𝑘𝑆)+𝑥𝑥(𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑆𝑆𝑅𝑅𝑅𝑅)−𝑘𝑘𝑘𝑘2)
where 𝜆𝜆𝑙𝑙𝑅𝑅𝑙𝑙 𝑜 1 − (
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸2
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸2𝑅𝑅𝑘𝑘𝑥𝑥
), where 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑅𝑅𝑘𝑘𝑥𝑥 is the maximum level that 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸2 can attain. We 
differentiate this as above. 
We take the derivative of this to embed it into the ODE set.
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For Rb = 1, the Rb controls are working correctly. In that case, low levels of the Cyclin 
E/CDK2 complex (ECDK2) will arrest the cell cycle, independently of SIAH and Reprimo 
levels. On the other hand, high levels of ECDK2 mean that the cell can pass through the G1-S 
transition, but SIAH or Reprimo might still stop it. We model this as a convex combination 
for the arrest signal:
Case Rb = 1:
𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 𝑜
1
; 
1 + 𝑜𝑜𝑘𝑘𝑘𝑘1∗(𝑥𝑥(𝑆𝑆𝑆𝑆𝑘𝑘𝑆)+𝑥𝑥(𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑆𝑆𝑅𝑅𝑅𝑅)−𝑘𝑘𝑘𝑘2)
Case 𝑅𝑅𝑅𝑅 𝑜 1: 
𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜λlow ∗ 1 + (1 − 𝜆𝜆𝑙𝑙𝑅𝑅𝑙𝑙)
1
1+𝑅𝑅𝑘𝑘𝑘𝑘1∗(𝑥𝑥(𝑆𝑆𝑆𝑆𝑘𝑘𝑆)+𝑥𝑥(𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑆𝑆𝑅𝑅𝑅𝑅)−𝑘𝑘𝑘𝑘2)
where 𝜆𝜆𝑙𝑙𝑅𝑅𝑙𝑙 𝑜 1 − (
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸2
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸2𝑅𝑅𝑘𝑘𝑥𝑥
), where 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑅𝑅𝑘𝑘𝑥𝑥 is the maximum level that 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸2 can attain. We 
differentiate this as above. 
where 𝜆
𝑙𝑜𝑤
= 1 − ( 𝐸𝐶𝐷𝐾2 ), where 𝐸𝐶𝐷𝐾2max is the maximum level that 𝐸𝐶𝐷𝐾2 can attain. 𝐸𝐶𝐷𝐾2𝑚𝑎𝑥
We differentiate this as above.
The final classification (into one of four states: 1, 2, 3, or 4) for the ground truth simulation 
uses the following rules, based on the levels at the end of the simulation:
If Apoptosis ≥ 0.8: 1 (apoptosis)
Else
If FIXED > 0.9 and ARREST < .5: 2 (repaired and cycling)
Else
If FIXED ≤ 0.9 and ARREST < .5: 3 (not repaired, and cycling, i.e. mitotic 
catastrophe)
Else 4 (quiescence)
For details on mutations and parameter changes used for ground truth dataset and the kernel 
dataset, see the MATLAB input files.
Flowering model
The flowering model is taken directly from Valentim et al. (2015)8. The outcome that we build 
a prediction model
for is flowering time, which, as in the original paper, is taken to be the time at which the protein 
AP1 exceeds a given threshold. The ODE model is simulated using MATLAB. The flowering 
model represents an isolated genetic circuit in multi-cellular eukaryote, and therefore as a 
model is a distant cousin—but a relevant one—to the vastly complicated genetic circuitry of 
human cancer cells.
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Boolean cancer model
The Boolean cancer model is taken from Cohen et al. (2015)9. We converted their GinSIM 
model into BoolNet format, which is a package in R. The authors provide an original model 
as well as a modular reduction. In the SimKern simulation we use the modular reduction, 
which represents a limited understanding of the model, further perturbed by uncertainties of 
how to map the feature data into this reduced model. The model output for both the ground 
truth dataset and the SimKern runs are based on the steady state vectors found by simulating 
the network for the given initial conditions. Let ss(n) denote the steady state value for node n. 
If the steady state is a fixed steady state, ss(n) will be a single value, either 0 or 1. If the steady 
state is a cycle, then ss(n) will be a binary vector of length equal to the cycle length. For the 
classification, we rely on two compartments in particular: n = Apoptosis and n = Metastasis. 
We classify the outputs into three categories using the following logic.
If all(ss(Apoptosis)) = 1: 1 (apoptosis)
Else
If all(ss(Metastasis)) = 1: 2 (metastasis)
Else 3 (other)
For details about the meaning of this model we refer the readers to the original publication9. 
In the present work, it is sufficient to view this model as an instance of a discrete complex 
system.
Network flow optimization model
We wrote a random network generation routine in MATLAB which generates a layer-wise 
directed graph. The user specifies the number of nodes for each layer and probabilities for 
adding a connecting arc between the nodes of two layers. We also add arcs between non-
adjacent layers with a small probability. We ran this routine once to create a single network 
for all the samples in the dataset, shown in Figure S2. We generate random numbers for the 
cost for these arcs. This represents the base network from which all the samples of SIM0 are 
built. Unique samples are created by varying the weights of 12 of the 80 arcs, the bold arcs in 
Figure S2. The outcome of the simulation is a classification, 1, 2, or 3, representing which of 
the last three arcs the optimal flow passes through (linear network flow optimization theory 
guarantees that there exists an optimal solution with all the flow through one of the exit arcs, 
and that such a solution will be returned by simplex-based methods10).
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Figure S4. Network flow directed graph. The bold lines are the arcs with variable costs in the ground truth simulation. 
The unit flow that enters the network at the uppermost node will exit through one of the labeled arcs at the bottom, 
which creates a classification problem.
We run two versions of SIM1, a less noisy model (with fewer perturbed, less noisy arc costs) 
and a noisier model (with larger number and higher magnitude of perturbed arc costs). For 
the less noisy models we assume the arc costs of the 12 SIM0 variable arcs are not known with 
certainty: they are scaled by a uniformly distributed random variable between 0.1 and 1.9. We 
also perturb every arc in the second layer by a uniform variable from 0.5 to 1.5. For the noisier 
model we additionally perturb the arc costs of the third layer (uniform 0.5 to 1.5) as well as a 
large perturbation, uniform between 9 and 10, of the third arc, which otherwise always takes 
the flow because of its otherwise low arc cost (see Figure S4).
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Supplementary results
Th e fl owering model, Figure S5, displays a typical “good kernel” result where the SimKern 
methods dominate the no-prior-knowledge methods throughout, but especially for small 
training set sizes. Similarity based NN is competitive with the more sophisticated similarity 
SVM and RF, but exhibits slightly more variance. Th e success of the SimKern methods 
indicates that the space induced by the similarity kernel is well behaved and the classes are 
easily separable with this kernel.
Figure S5. Machine learning results for the fl owering model. NN = nearest neighbor, RF = random forest, SVM = 
support vector machine, RBF = radial basis function. R2 is the coeffi  cient of determination.
With the network fl ow model, we demonstrate the obvious but important result that if the 
SimKern simulation is farther from the ground truth simulation due to additional noise, 
the SimKern learning will be worse. Th e kernel based on a less noisy SimKern simulation, 
Figure S6, displays dominance throughout whereas the kernel based on a noisier SimKern 
simulation, Figure S7, is overtaken by the standard RF already by 18 training samples. We 
also used vector-based outputs from the SIM1 simulations, where the fl ow through every arc 
was used to compute similarity scores. Th e results were not fundamentally diff erent so here 
we display results from only the scalar based SIM1 output.
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Figure S6. Machine learning results for the network fl ow optimization model for the less noise case. NN = nearest 
neighbor, RF = random forest, SVM = support vector machine, RBF = radial basis function.
Figure S7. Machine learning results for the network fl ow optimization model for the more noise case. NN = nearest 
neighbor, RF = random forest, SVM = support vector machine, RBF = radial basis function.
Th e SimKern idea is eff ective provided that the simulations correctly judge the similarity 
between two samples, but the SimKern simulations need not themselves make correct 
predictions (in fact, the raw output of the SimKern simulations need not be the same type of 
output as we are trying to predict). To illustrate this, we examine the fi rst 13 samples from the 
dataset for the network (lower quality) model, see Figure S8. Samples 2 and 11, which both 
are classifi ed as 3s in the ground truth dataset, are given a high similarity score because they 
behave similarly for most of the 10 trials, even though in only one of those trials (trial 6) are 
they actually classifi ed correctly.
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Each model displays two nearest neighbor (NN) algorithm learning results: the default 
method which is Euclidean distance in feature space, and the kernelized method which uses 
the simulation based similarity scores for the distance computation. Consistently, the kernel 
based NN methods dominates over standard NN, which implies the power of a custom 
similarity measure. The difference between either of these NN methods and the SVMs display 
the power of better machine learning algorithms: rather than classifying a new sample based 
on which training sample it is closest to, SVMs factor in the distance to many of the training 
samples. In some cases (Figure 3, main document: the radiation model with the higher quality 
kernel, and Figure 4 main document or Figure S5: the flowering model) we see that a good 
similarity score is ultimately good enough and more advanced machine learning algorithms 
do not offer much improvement over the kernelized NN.
Figure S8. SIM1 results for the first 13 samples from the network (lower quality) dataset, for all ten trials and also 
showing in the bottom yellow row the ground truth (SIM0) result. We have highlighted samples 2 and 11. These 
samples are both 3s in the ground truth set, but in the R = 10 SimKern (SIM1) trials they get correctly classified only 
once. However, they are given a high similarity score since they behave the same for most of the trials. We use this to 
highlight the idea that it is sufficient to correctly judge sample similarity; accurate class prediction is not necessary.
As an additional way to compare machine learning results in the case of regression (the 
flowering model), Figure S9 plots the predicted flowering times versus the actual flowering 
times. With additional training samples (13 to 25), linear SVM and, even more so, SimKern 
SVM improve their predictions for samples with a flowering time < 6. After training on 
additional data, one observes a small additional downward bias in linear SVM predictions for 
samples with a flowering time > 10. Both algorithms, however, achieve an R2 improvement by 
0.19 (linear SVM) and 0.31 (SimKern SVM).
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Figure S9. Observed and predicted test set values after training on 13 (left) and 25 (right) samples for the 
flowering time model. Results for linear SVM and SimKern SVM are in orange and green, respectively. 
Left: R2 equals 0.27 and 0.66 for linear SVM and SimKern SVM, respectively. Right: R2 equals 0.46 and 0.97 for linear 
SVM and SimKern SVM, respectively.
A word on the “kernel trick”
Kernel methods are often touted in the literature as a cure-all for the problem of overly high 
dimensional samples: by kernelizing the data, the high dimensionality goes away. In fact, 
kernelizing data does not so cleanly solve this problem since there are many ways to make a 
kernel. Only when considering highly restricted kernel classes such as linear kernels or RBF 
kernels, without any feature weighting or feature selection, does the kernel trick simplify the 
search for a good machine learning approach. But in general, we do not know how to build 
a good kernel (that is, how to judge similarity between two samples in a way that is most 
effective for our machine learning problem). We propose herein to distill expert knowledge of 
a domain into simulations that use the high dimensional features, which pre-supposes quite 
detailed knowledge of the system. If such detailed knowledge is not available, the number 
of ways to turn a large feature set into a kernel is unmanageable (consider combinatoric 
calculations for example of selecting 200 genes out of 20000 to test all sets of 200 genes). We 
state this here as a word of caution: the kernel approach can be very useful but it requires 
obtaining a good kernel, and there is no general recipe for that.
Clearly for the SimKern approach to work, the simulations used to generate the kernel have 
to be “good”, but unfortunately, it does not seem possible to be more quantitative than that for 
general cases. We explored the issue by demonstrating that as we veer away from high quality 
simulations, the machine learning using the custom kernel does worse (see e.g. Figures S6 
and S7), but it will always be a data- and problem-specific analysis to see if a proposed kernel 
is useful.
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The previous chapters have addressed innovations and findings to foster machine learning for 
radiotherapy and medical research:
• distributed data infrastructures (chapters 2 & 3),
• how to train prediction models in such distributed setting (chapters 2 & 3),
• a systematic comparison of machine learning algorithms on clinical data (chapter 4),
• a new method to combine simulation studies and kernelized machine learning algorithms 
(chapter 5).
In this chapter, I will discuss challenges to successfully establishing distributed data 
infrastructures and to the use of machine learning in radiotherapy research.
Distributed data infrastructures
A major aspect of the distributed learning projects described in chapters 2 & 3—besides the 
actual learning of prediction models—is creating access to patient databases distributed over 
hospitals, thereby increasing the amount of patient data available for machine learning. The 
advantages of distributed data storage and access for research have been discussed in chapter 2.
However, this data infrastructure faces multiple challenges. I will elaborate on the two most 
prominent challenges: infrastructure sustainability and acceptance by the research community. 
Infrastructure sustainability
Sustainability of the distributed data infrastructure introduced with euroCAT (chapter 2) and 
extended in follow up projects such as The Personal Health Train (chapter 3) depends on 
proper technical implementation and continuous maintenance.
Firstly, sustainable technical implementation of the distributed learning infrastructure 
does not coincide with the goals of funding agencies and professional goals of researchers. 
Distributed learning research projects are funded by public research grants which are limited 
to a few years and the implementation is carried out by, among others, junior researchers with 
short term goals. The success of research projects and the performance of junior researchers 
is evaluated by the quantity and quality of published manuscripts within the funded period. 
Manuscripts highlight individual results and are not suitable for assessing the technical quality 
of infrastructure implementations. Therefore, working towards publishable findings will take 
precedence over implementation quality.
Furthermore, software is developed by researchers-in-training rather than professional 
software developers. The development process may, therefore, also be their first large 
implementation experience.  As a consequence, the resulting product is more similar to a 
prototype than a tool for universal use.
Secondly, continuity in technical maintenance and project management are threatened 
by lacking financial support in common research financing schemes and researcher 
turnover. After completing research for a given grant and the corresponding funding ends, 
infrastructure maintenance drains hardware and human resources of local hospitals. Unless a 
follow-up grant is acquired or local researchers are motivated to raise internal support for the 
maintenance of the local infrastructure components, the infrastructure endpoint is removed 
and future access to data is wasted. These issues where factors contributing to the loss of 
the euroCAT infrastructure (chapter 2) after completion of the project. To reduce the risk 
of losing old endpoints, collaborating hospitals need to be actively involved in the research 
project to emphasize the infrastructure’s benefits and invoke local researchers’ support for the 
infrastructure after the research funding has been depleted.
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Another risk for the continuity of the infrastructure is that academic research projects and the 
corresponding knowledge are centered on individual researchers. As customary in academia, 
PhD students quit the project after graduation and post-doctoral researchers are likely to 
change employers in the search of tenure track positions. The resulting employee turnover—
combined with the difficulties to organize extensive knowledge transfer in complex research 
projects—hinders continuity in academic infrastructure projects.
For the distributed data infrastructure to succeed in the long run, a permanent funding 
source needs to be uncovered. Permanent funding will finance resources to keep existing 
infrastructure and (permanently) employ qualified personnel to maintain and develop 
software for general use. The first step towards this goal has already been taken when the 
Health-RI initiative (an umbrella initiative with structural funding, for projects such as 
euroCAT and The Personal Health Train) was placed on the KNAW agenda for large-scale 
research facilities1.
Infrastructure acceptance
The long-term vision of distributed data infrastructures is to provide access to routine clinical 
care data in (all) radiotherapy institutes worldwide to boost machine learning research in 
radiotherapy and provide insights that are useful in clinical practice. The path towards this 
utopia is long and requires continuous support by researchers, administrators, and funding 
bodies. Acceptance by researchers is crucial, especially by those who are only users and not 
also developers of the infrastructure, because only proof of a wide user base will convince 
governmental funding agencies to finance an (inter)national roll-out of the infrastructure.
Creating acceptance among researchers is a weak point of this distributed data infrastructure: 
the user experience in the distributed data analysis process is fundamentally different from the 
current centralized data analysis process known to researchers. The main difference is that the 
researcher cannot view the data while working on the analysis. Instead, they have to rely on 
summary statistics and model coefficients returned by each hospital. Furthermore, convenient 
data pre-processing and statistical functions present in established software packages are not 
readily available and need to be implemented for the distributed setting. Both aspects cause 
inconvenience to the researcher and likely result in preference for the existing centralized 
data analysis. It is possible to alleviate the inconvenience by developing software packages 
for distributed data analysis with a wide range of commonly used functions. However, 
improving the user experience will require time and resources that are predominantly spent 
on generating publishable results (see above). Furthermore, a strategic decision would need 
to be made on which software solution to support. Currently, even within our research 
group, which is developing the distributed data infrastructure, there is no consensus on the 
distributed learning framework (Varian Learning Connector or an open-source alternative) 
or on the programming language used to process data and train machine learning algorithms 
(MATLAB, R, Python, or Java). In their analysis of large historical infrastructure projects 
(e.g., electricity networks, internet), Wittenburg and Strawn (2018)2 name this phase 
‘creolization’: exploring various possible solutions before converging to universal standards 
which then enables large scale exploitation of the infrastructure. In our case, we need to 
shorten or postpone this exploration of possible solutions in exchange for quickly developing 
a preliminary but stable and user-friendly infrastructure to increase confidence with funding 
agencies. Achieving user acceptance and securing institutional support for the distributed 
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data infrastructure are more valuable for proliferating machine learning in radiotherapy than 
academic squabbles over optimal infrastructure designs.
One particular design choice in the distributed data infrastructure bears the risk to 
hamper acceptance among researchers: in each hospital, patient features are mapped to 
standardized terms in an ontology (e.g., the ROO ontology3) and data tables are translated 
into triples. Patient data is then queried using SPARQL4. The advantages of semantic web 
technology lie in the urgently needed feature standardization and reasoning capabilities. 
While adopting this versatile technology may be beneficial in the long run, it poses multiple 
difficulties that threaten acceptance of the distributed data infrastructure. Firstly, users 
changing from centralized to distributed data analysis will not only have to accept the lack 
of visual access to the data and limited analysis functionality (see above), but they will also 
have to learn and use the, arguably complex, SPARQL. Secondly, when researchers wish to 
investigate a novel feature collected at some hospital, it will first need to be defined in the 
corresponding ontology before it can be mapped to triples and eventually be queried by 
the user. The same problem occurs for existing but less common features that were not yet 
defined in ontologies. Ontology design is a complex task in itself and will probably reside with 
specialized individuals which means that progress in the user’s research will depend on the 
availability of key developers/maintainers of the distributed data infrastructure. This process 
may become lengthy and obscure to a user who initially ‘just wanted to query a column’. 
There are alternatives to semantic web technology, e.g., storing features in relational databases 
defined by a (local or global) data dictionary accessed using SQL. Settling with a less flexible 
but established method would offer the advantage that it will not overburden new users of 
the distributed data infrastructure. Nonetheless, it is difficult to choose between introducing 
a future-proof technology and conventional methods for the sake of acceptance. The former 
will, however, require substantial user training and support so that the distributed data 
infrastructure becomes a success.
In conclusion, unless significant effort and resources are put into simplifying the user 
experience, the aforementioned drawbacks—lack of visual access to data, limited functionality, 
parallel introduction of semantic web technology—may severely hamper user acceptance and 
consequently adoption of distributed data infrastructures in radiation oncology.
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Machine learning methodology and publications
Machine learning has received great attention in the research community but we are yet to see 
a machine learning application in oncology that changes clinical practice. Commercial high-
profile projects have been met with anticipation, but the case of IBM Watson for Oncology 
exhibits a discrepancy between advertised benefit and clinical reality5: instead of AI-generated 
treatment recommendations, it is said to provide advice trained by medical doctors.
Barring clinical implementation, already at the level of scientific publications, the 
undifferentiated use of machine learning methods and overstating findings will disappoint and 
eventually tire the audience, publicly flawing the concept of machine learning in radiotherapy. 
The hype surrounding machine learning should not tempt researchers to overestimate 
capabilities of machine learning algorithms and ignore scientific standards. Specifically, not 
all prediction tasks in radiotherapy become solvable by using more complex machine learning 
algorithms or by sequentially trying many different algorithms.
In chapter 4 we have shown based on 12 radiotherapy datasets that classifiers perform 
differently across datasets and one can pick a better classifier for a certain dataset—but we 
also see that the more complex algorithm is not always the best choice, e.g., a single hidden 
layer neural network performs worse than a simpler penalized logistic regression.
For an algorithm to correctly predict outcomes of a patient,
• the necessary information needs to be present in the patient’s data,
• the algorithm needs to have been trained on sufficient patient cases to correctly separate 
useful and unnecessary information,
• the algorithm needs to be complex enough to correctly model the information.
When a simple algorithm fails patient predictions, the problem might lie in any of the three 
conditions. As machine learning research in radiotherapy is chronically short on patient 
data, the easiest solution is to replace the algorithm and redo the training and validation. 
Adjusting the algorithm (and therefore the underlying model) to the classification problem 
is a legitimate and recommendable step in the modelling process. If done correctly, it allows 
assessing the added benefit of a change in algorithm complexity. Extending the analysis to 
multiple algorithms, however, also bears a risk to flaw the analysis: training and validating 
different algorithms on a fixed pair of training and validation datasets is a clear case of 
multiple hypothesis testing and needs to be taken into account.
The now available array of machine learning algorithms therefore adds yet another way to 
(unintentionally) report overly optimistic modelling results. Increasing the algorithm’s 
complexity can conveniently be justified as ‘using innovative methods’ in the current machine 
learning buzz. (Similarly, decreasing algorithm complexity could be defended as ‘conservative 
modelling’ following Occam’s razor.)
For that reason, researchers need to become aware of these pitfalls. When deliberating the 
use of more complex machine learning algorithms, they should ask themselves whether the 
lack of algorithm complexity is the most likely cause of poor predictions or whether it is 
more probable that they train their algorithm on unrealistically few patient cases and/or 
uninformative features.
If indeed too few patient cases or uninformative features are used and there is no reasonable 
way to get access to more data or better features, pure machine learning approaches might 
not be able to solve the prediction tasks. A way to possibly improve models is to add domain 
knowledge: e.g., expert-guided feature selection6,7, expert-built decision trees or expert-
validated prediction models8. Expert knowledge is, however, not without flaws: when asking 
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experts to predict treatment outcomes for patients, they perform worse than fully data-
driven machine learning algorithms9. Therefore, it needs to be assessed for which step in the 
modelling process expert knowledge can be of added value.
Related to the goal of including domain knowledge during the machine learning modelling 
process, we have described a new general methodology (chapter 5) that allows incorporating 
(biological) simulations in kernelized machine learning algorithms. While this will certainly 
not solve the problem of limited data and uninformative features, it is an avenue to combine 
the vast, decade-old expertise on biological simulations with the now popular machine 
learning algorithms.
To preclude a ‘replication crisis’ as observed in other fields10,11, more rigorous standards need 
to be adopted for machine learning research in radiotherapy. It is good to see that standards 
like the TRIPOD statement12, which defines steps to assess prediction model performance, 
are already used for machine learning research in radiotherapy. For radiomics studies, we 
proposed the radiomics quality score (RQS)13 to assess manuscript quality. To further avoid 
mistakes in the statistical analysis of machine learning algorithms and reduce pressure 
on researchers to present only positive results, ‘pre-registration’ of studies14,15 should be 
promoted: a study design is peer-reviewed and accepted before data is collected and analyzed, 
the eventual result will be accepted regardless of the conclusions. The counter argument that 
pre-registration would stifle valuable exploratory analyses is invalid as pre-registration will 
still allow reporting additional results in the final report although labelled as ‘exploratory 
analysis’ as argued in Chambers et al. (2013)14.
Radiotherapy and medical physics journals would do machine learning researchers a service 
if they introduced and promoted study pre-registration.
Future prospects
In the optimal case, distributed data infrastructures will receive nationwide support by the 
Dutch government to collect and standardize patient features as exemplified in The Personal 
Health Train project (chapter 3). Recent developments show that there is indeed public 
interest in the concept of distributed data infrastructures. Distributed data infrastructure 
collaborations are being initiated between, e.g.,
• the Dutch and Taiwanese cancer registry16,
• Statistics Netherlands (CBS) and the Maastricht Study on Diabetes,
• health insurers (Vektis) and government agencies (NZA),
• Dutch proton therapy centers (PROTRAIT) and Limburg health care providers (LIME).
Likely, the nine Dutch university medical centers, of which four participate in the duCAT 
project and one is aspiring to join follow-up projects, will take a leading role to extend the 
distributed data infrastructure and develop distributed machine learning models through the 
aforementioned Health-RI initiative. Regional hospitals will act as data providers and users 
of the resulting machine learning models. Until nationwide adoption is realized, academic 
projects will need to continue highlighting the use of this infrastructure and the benefits for 
radiotherapy. As stressed earlier, infrastructure sustainability and usability need significant 
attention.
The use of machine learning applications in radiotherapy clinics will be inevitable. Only 
the extent to which they will assist medical professionals in the radiotherapy process will be 
affected by how machine learning research will be conducted and communicated in the near 
future.Machine learning applications to help with repetitive, time consuming but somewhat 
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easier tasks such as metastatic node detection17 or organ and tumor delineation18 will soon 
be adopted in clinical care. Delegating complex decision making processes, such as treatment 
selection between chemoradiotherapy versus radiotherapy only, to machine learning 
models will require unwavering trust in and understanding of these algorithms by medical 
professionals. Obscure machine learning methodology and a publication culture with non-
replicable results will undermine the necessary trust.
Once a machine learning application has been developed, prospectively validated in clinical 
trials, and approved for medical use, it will enter radiotherapy clinics like any other technology: 
the algorithm will need to be commissioned in each clinic using local patient data. Therefore, 
machine learning models will also become available for smaller clinics without their own 
active research groups.
Conclusion
There is still a long way ahead of us for machine learning algorithms to change radiotherapy 
practice. The enthusiasm in the scientific community to develop practice-changing machine 
learning applications is high. We need to use this momentum while it lasts to lay the 
groundwork for a sustainable future of machine learning in radiotherapy: an established 
distributed data infrastructure with first simple but robustly validated machine learning 
applications. In this thesis, we have tried to contribute to both goals with data infrastructure 
prototypes (chapters 2 & 3), analyses of machine learning algorithms (chapter 4), and a new 
machine learning methodology (chapter 5). In this way, once the novelty and excitement have 
ebbed away, the impetus will not have been wasted on short-term gains, but the foundations 
will have been laid out and the work can continue.
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This thesis discusses machine learning methods to analyze patient data in radiation oncology. 
Due to the increasing availability of computing power, digitalization of medical records, 
and the success of machine learning in other fields, increasingly sophisticated data analysis 
procedures are sought after also in the medical sciences. In radiation oncology, such machine 
learning methods might improve the prediction of radiotherapy outcomes for individual 
patients, which could aid physicians and patients in selecting suitable treatments. Current 
research efforts are dedicated to attaining a thorough understanding of the existing machine 
learning methods and how they can be used for treatment outcome prediction.
Furthermore, developing reliable machine learning applications requires access to large 
amounts of patient data. Patient data is stored by each healthcare provider and collaboration 
between these healthcare providers is needed to reach sufficient patient data volumes. 
Regulatory barriers to protect patient-privacy complicate sharing patient data across healthcare 
providers and therefore hamper the implementation of machine learning applications 
in clinical practice. Technological solutions are needed to allow machine learning across 
healthcare providers while meeting privacy regulations. The existing concept of distributed 
learning might pose a solution, i.e. training machine learning algorithms on patient data 
stored at distinct healthcare providers without patient data being exchanged.
The studies presented in this thesis form two parts:
• the development of a distributed learning infrastructure to facilitate privacy-preserving 
machine learning studies across healthcare providers
• the analysis of existing machine learning methods in the context of radiotherapy outcome 
prediction and the development of a new machine learning method.
With a small proof-of-concept study in chapter 2, the distributed learning infrastructure 
was described and it was shown that distributed learning across radiotherapy institutes is 
possible. Support vector machine models to predict post-radiotherapy dyspnea (grade 2 or 
higher) were trained on lung cancer patient data from five radiotherapy clinics located in 
three countries (Belgium, Germany, The Netherlands).
To demonstrate the infrastructure’s scalability, another study in chapter 3 applied this 
infrastructure in eight healthcare providers across five countries (China, England, Italy, The 
Netherlands, Wales) to train and validate a logistic regression for predicting post-treatment 
two-year survival based on tumor staging data of more than 20 000 non-small cell lung cancer 
patients. This study was executed in four months demonstrating the distributed learning 
infrastructure’s potential for fast-paced machine learning studies.
In a study of existing machine learning methods for (chemo)radiotherapy outcome 
prediction (chapter 4), the discriminative performance of six machine learning algorithms 
(decision tree, random forest, neural network, support vector machine, elastic net logistic 
regression, LogitBoost) was compared and ranked on twelve patient data sets. Random forest 
and elastic net logistic regression showed a small increase in discriminative performance. 
These findings might guide researchers in selecting appropriate machine learning methods 
for future studies.
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Finally, a new kernelized machine learning approach was presented in chapter 5, which allows 
combining simulation models and machine learning methods. Both simulations and machine 
learning methods allow inferring predictions: simulation models use prior knowledge gained 
by (experimental) analysis of a system while machine learning methods derive predictions 
from data with statistical means. The presented results from four synthetic scenarios indicated 
that merging simulation models and machine learning methods might pose an advantage in 
scenarios where insufficient data is available to train standard machine learning algorithms.
Chapter 6 discussed challenges and future prospects for distributed learning infrastructures 
and the use of machine learning methods in radiation oncology. Challenges for distributed 
learning addressed in this chapter are infrastructure sustainability and its acceptance by users. 
Furthermore, the risks of misusing machine learning methods and overstating results, and 
how reporting standards and pre-publication registration of studies can mitigate negative 
consequences are considered.
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For distributed data infrastructures and machine learning algorithms to last in radiotherapy, 
they need to add value to society and/or be capitalized in the private sector.
Distributed data infrastructures may form integral parts of future radiotherapy clinics for the 
benefit of society and each individual patient. Therefore, (inter)national governments may 
decide to mandate it for healthcare providers.
It is in the interest of the public to
• foster access to patient data for medical research,
• control the quality of care by healthcare providers,
• ensure patient privacy and control over the data.
Distributed data infrastructures support these three aspects. It is possible to apply machine 
learning algorithms or other kinds of data analysis processes via the infrastructure. Similarly, 
it is possible to compare treatments across clinics using statistical analyses. Most importantly, 
the data always remains at the institute where the data was generated (i.e. where the patient 
was treated) and the external analyst does not have direct access to the data. Standardization 
of medical data on an (inter)national level may pose the biggest challenge which is, however, 
inevitable regardless whether centralized or distributed data infrastructures are used. 
Therefore, it will be in the interest of public health to support or even prescribe participation 
in distributed data infrastructures for radiotherapy clinics.
Distributed data infrastructures also have commercial applications: medical research 
companies require access to patient data for pharmaceutical, device, or software development. 
A distributed data infrastructure would provide patients a platform to sell restricted access to 
their data while maintaining control and ensuring anonymity.
The Varian Learning Portal1 (chapters 2 & 3) is evidence that the private sector sees promise 
in distributed data infrastructures for radiotherapy: it is free to use for radiotherapy clinics to 
learn prediction models using data from participating institutes but Varian has the first right 
of refusal for commercialization of the resulting models.
Machine learning algorithms for radiotherapy (and other medical applications) have 
applications with substantial benefit to society and clear commercialization prospects.
Machine learning models have the potential to assist medical professionals in repetitive tasks 
and complex decision-making processes:
• organ/tumor delineation2,
• treatment planning quality control3,
• decision support systems for treatment selection4.
Most notably, the guidelines to select patients for proton therapy in the Netherlands prescribes 
a model-based decision process in which patient cases with certain diagnoses will be evaluated 
using (machine learning) models5.
Reducing the time spent on these tasks saves resources and thus decreases public healthcare 
spending. Assisting medical professionals in making better decisions improves healthcare 
outcomes. Therefore, society will benefit if properly tested machine learning models become 
part of the radiotherapy process.
146 VALORIZATION
The development of machine learning models for medical applications is a long and 
expensive process in a heavily regulated industry but with a large global market. Individual 
hospitals, whose only focus is to treat their patients, will hesitate to pursue this enterprise 
given the high costs but private investors and multinational companies have the means and 
interest to finance the development at the prospect of high future payoffs. IBM Watson for 
Oncology6 is an example for a large multinational corporation to develop decision support 
systems for oncology but investors also finance small businesses: two examples originating 
from Maastricht University/MAASTRO clinic are ptTheragnostic B.V.7, which is working 
on decision support for proton radiotherapy, and Oncoradiomics SA8, which is working on 
image-based biomarkers for radiotherapy.
In conclusion, distributed data infrastructures and machine learning algorithms 
for radiotherapy have clear valorization prospects both for the benefit of society and 
commercialization.
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